

# Machine learning and new insights for breast cancer diagnosis

Journal of International Medical Research 2024, Vol. 52(4) 1–29 © The Author(s) 2024 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/03000605241237867 journals.sagepub.com/home/imr



Ya Guo<sup>1</sup>,\*, Heng Zhang<sup>2</sup>,\*, Leilei Yuan<sup>1</sup>, Weidong Chen<sup>1</sup>, Haibo Zhao<sup>1</sup>, Qing-Qing Yu<sup>3,†</sup> o and Wenjie Shi<sup>4,†</sup> o

#### **Abstract**

Breast cancer (BC) is the most prominent form of cancer among females all over the world. The current methods of BC detection include X-ray mammography, ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography and breast thermographic techniques. More recently, machine learning (ML) tools have been increasingly employed in diagnostic medicine for its high efficiency in detection and intervention. The subsequent imaging features and mathematical analyses can then be used to generate ML models, which stratify, differentiate and detect benign and malignant breast lesions. Given its marked advantages, radiomics is a frequently used tool in recent research and clinics. Artificial neural networks and deep learning (DL) are novel forms of ML that evaluate data using computer simulation of the human brain. DL directly processes unstructured information, such as images, sounds and language, and performs precise clinical image stratification, medical record analyses and tumour diagnosis. Herein, this review thoroughly summarizes prior investigations on the application of medical images for the detection and intervention of BC using radiomics, namely DL and ML. The aim was to provide guidance to scientists regarding the use of artificial intelligence and ML in research and the clinic.

#### Corresponding author:

Wenjie Shi, Molecular and Experimental Surgery, University Clinic for General-, Visceral-, Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital Magdeburg, Otto-von Guericke University, 39120 Magdeburg, Germany.

Email: wenjie.shi@uni-oldenburg.de

<sup>&</sup>lt;sup>4</sup>Molecular and Experimental Surgery, University Clinic for General-, Visceral-, Vascular- and Trans-Plantation Surgery, Medical Faculty University Hospital Magdeburg, Otto-von Guericke University, Magdeburg, Germany

<sup>\*</sup>These authors contributed equally to this work.

<sup>&</sup>lt;sup>†</sup>These authors contributed equally to this work.

Department of Oncology, Jining No.1 People's Hospital, Shandong First Medical University, Jining, Shandong Province, China

<sup>&</sup>lt;sup>2</sup>Department of Laboratory Medicine, Shandong Daizhuang Hospital, Jining, Shandong Province, China <sup>3</sup>Phase I Clinical Research Centre, Jining No. I People's Hospital, Shandong First Medical University, Jining, Shandong Province, China

## **Keywords**

Breast cancer, machine learning, radiomics, artificial intelligence, deep learning

Date received: 21 August 2023; accepted: 21 February 2024

### Introduction

Breast cancer (BC) is the most prominent malignant tumour among females worldwide and it accounts of almost 10.4% of all cancers. 1 It is characterized by an aberrant, disorderly, and invasive proliferation of breast cells. Moreover, BC cells can readily escape to the circulatory or lymphatic system, where they generate new tumours and invade distant vital organs.<sup>2</sup> At present. BC is the largest contributor to cancerrelated mortality among women between 20-50 years of age. Based on information from the American Cancer Society, in 2019 alone, there were an estimated 268 600 new incidences and 41 740 cancer-associated deaths in the United States.<sup>2</sup> Alarmingly, in 2020, the cancer-related mortality among women increased to 684 996 global deaths, making it the major contributor of deaths across the globe. In addition, in 2021, the World Health Organization announced BC as the most prevalent form of global cancer, far exceeding lung cancer.1 At present, these numbers are rapidly increasing, and a 50% rise is predicted over the next two decades to enhanced life expectancy, owing unhealthy diets, inadequate physical activity and detrimental substance intake (for example, alcohol). Given these critical factors, there is an urgent need for extensive research in all areas of BC, from prevention early detection and efficacious intervention.<sup>2,3</sup>

Personalized BC interventions are highly dependent on accurate diagnosis. BC typically features discrete histological, molecular and clinical phenotypes; and it sometimes manifests with radiological

heterogeneity. Nevertheless, classical detection techniques do not provide adequate information for proper BC diagnosis.4 Radiomics is a relatively new tool for the extensive analysis of medical images. The subsequent imaging features and mathematical analyses can then be used to generate machine learning (ML) models, which stratify, differentiate, and detect benign (b-BT) and malignant breast lesions (m-BT), which, in turn, can be used to establish risk and formulate the optimal intervention for patients with b-BT and/or m-BT. Relative to classical influential science and skilled radiologists, radiomics features offer a more precise diagnostic method of BT detection. Hence, radiomics-based explorations/research are well underway in different parts of the world.<sup>5</sup>

More recently, scientists increased the application of ML tools, namely, image segmentation, stratification and estimation for BC assessment. Image segmentation both identifies and extracts tumour and its adjoining normal tissue. ML tools, particuconvolutional neural (CNNs), are widely employed for automated BC segmentation. For example, a previous study established a CNN-based algorithm, with a mean dice similarity coefficient of 0.85, to segment BC tumours in ultrasound images. 6 Stratification delineates between m-BT and b-BT and predicts the probability of recurrence or metastasis. ML tools, namely, support vector machines (SVMs) and random forests (RFs), are frequently applied in BC stratification. For example, previous research established an RF-derived algorithm for breast tumour stratification of


mammograph images, using a sensitivity (SEN) and specificity (SPC) of 87.5% and 91.7%, respectively. Prediction estimates the probability of tumour recurrence or metastasis, as well as treatment response. ML techniques, namely, deep neural networks (DNNs) and recurrent neural networks (RNNs), are also widely employed for BC estimation. For example, a study reported a DNN-derived method for estimating BC recurrence risk, with an area under the receiver operating characteristic curve (AUC) of 0.87.

Medical imaging, namely, X-ray mammography (MG), magnetic resonance imaging (MRI) and positron emission tomography (PET), offers a non-invasive approach of extracting data on BC morphology, metabolism and blood flow. Radiomics, a progressive tool for the isolation of quantitative profile from medical images, has garnered much attention owing to its ability to retrieve both spatial heterogeneity and functional profiles of tumours. BC imaging has made remarkable recent progress, with marked advancements in both technology and imaging analyses. The common approaches of BC detection encompass MG, ultrasound (US), MRI and molecular imaging. Using these techniques, it is now possible to detect and diagnose earlystage BC, which ultimately enhanced patient prognoses. Moreover, ML and deep learning (DL) algorithms are also applied in BC image analysis, with promising results. Herein, this review presents a detailed summary of the current ML applications for BC imaging, namely, MG, ultrasound, MRI, PET and others. The article selection process is detailed in supplemental information. Based on the module and search string in PubMed<sup>®</sup> (see supplementary materials, Table S1) and Web of Science<sup>TM</sup> (see supplementary materials, Table S2), a retrieval strategy of the above respective databases was established (see supplementary materials, Table S1). Overall, 158 articles were selected from the date of inception of the databases up to 31 May 2023. Figure 1 shows the results of the literature search and selection.

# X-ray mammography

X-ray mammography is routinely used to screen and diagnose BC, and it is a wellestablished method of minimizing cancerassociated deaths. BC tumours are initially screened using X-ray mammography, prior to manual interpretation by a radiologist to estimate whether it is b-BT and m-BT. The popularity of MG stems from its reduceddose X-ray, enhanced-contrast, augmentedresolution detectors and X-ray system particularly intended for breast imaging. In general, MG can be separated into two groups: film screen MG (FSM), whereby a film screen serves as the end-recording device; and full-field digital MG (FFDM), whereby digital detectors serve as the recording media. Digital images from FFDM provide numerous benefits over FSM, particularly in terms of ease of image processing and enhancement.4

In recent times, there has been a considerable rise in artificial intelligence (AI) algorithm use in medicine. The available AI includes radiomics and DL, which markedly enhances lesion detection and diagnosis from medical images in clinical practice. 10,11 The current AI is rather sophisticated and approaches the performance of a skilled radiologist, particularly in MG.12 MG images, photographed and quantified using radiomics, offer a remarkable diagnostic capacity for b-BT and m-BT, and they also provide other relevant data to radiologists.4 To further augment MG screening accuracy, the computer-aided diagnosis system (CAD) software 4 was designed for BC tumour identification and used since the 1990s. Regrettably, information from earlier CAD systems did not yield any marked improvement in patient outcome. 13,14 With significant advancements



**Figure 1.** Flow diagram showing the identification of the research articles describing the current machine learning applications for breast cancer imaging that were included in this review.

in DL visual object identification, and multiple other domains, more scientists are showing interest in establishing DL tools the MG screening of augment women. 15-18 Emerging evidence suggested that the performance of a DL-based CAD system was comparable to the radiologist performance alone, and enhanced the radiologists' performance in a supporting mode. 19,20 One study introduced a collaborative DL method that clearly classified pathological images into cancerous and non-cancerous BC tissues on 544 complete whole slide images, with SEN and accuracy of 97.73% and 95.29%, respectively. 19

Machine learning is a form of AI introduced in the 1980s. ML primarily examines how computers mimic human learning

behaviours, procure novel information, enhance existing information, as well as their own performance. ML conducts tasks without clear programming directions, namely, it identifies hidden associations between data and analyses them. Among the common ML applications are logistic regression (LR), linear regression, decision trees, RFs, naive Bayes and K-means cluster analyses, multilayer perceptron (MLP) and SVMs.21 Artificial neural networks (ANN) and DL are novel areas of ML and these tools analyse data using computer simulation of the human brain. ANN is based out of the biological learning mode of human brain neurons that interconnect with one another, and regulate cascade, alteration and classification. DL is

more advanced than ANN. DN utilizes the hierarchical ANN to establish highly complicated learning models that elucidate data in various dimensions. DL encompasses a dynamic Bayesian network, CNN and RNN. The CNN algorithm distinctly benefits image processing and is employed in feature isolation and analysis of clinical imaging information. Recursive neural network algorithms dynamically monitor disease via time series data analysis. Traditional ML requires feature extraction from the original data, as well as processing into structured datasets, which cannot directly process unstructured data. DL also directly processes unstructured information, such as images, sounds and language; and is highly beneficial in clinical image stratification, medical record analysis and tumour diagnosis. 22,23 Thus, multiple strategies are implemented in mammogram diagnosing. These can be classified into sta-Markoviantistical-, wavelets-, machine-learning-based methods.<sup>24</sup> A previous study developed a region of interest (ROI)-based CNN termed You Only Look Once, which simultaneously identified and categorized breast masses into digital mammograms.<sup>25</sup> This model was composed of distinct phases, namely, preprocessing, feature retrieval, mass detection with belief and tumour stratification with fully connected neural networks. However, this model was not appropriate for a small dataset and the tumour area was not partitioned within mammograms. To classify MG mass lesions and examine the CNN model, researchers developed deep convolutional neural networks. 21 Upon preprocessing and normalization of isolated ROIs from the entire mammogram, the ROIs were integrated to form a unified dataset, which was then used to update the CNN. However, this technique did not minimize noise or muscles, which potentially resulted in mis-stratification.

Machine leaning, particularly breast imaging CAD system, aids in BC tumour diagnosis, and it is not influenced by the radiologist's reading mode, fatigue, distraction and other factors. Therefore, this system greatly enhances SEN of BC diagnosis.<sup>22</sup> Researchers examined an AI system's aptitude to substitute for doctors in BC diagnosis. 19 The study revealed that the AI systems are quite efficient, relative to radiologists, in BC detection. 19 Another study also evaluated cytological image analysis for BC identification and stratification using Naive Bayesian and ANN, demonstrating 98% precision in BC detection.<sup>23</sup> Similarly, Another study reported an enhanced crow search optimized extreme learning machine process, with approximately 98.26%, 97.193% and 98.137% accuracies for the reast, DDSM and MI -AS datasets, respectively.<sup>26</sup> Researchers developed a CAD system involving two components as follows: the first component identified an ROI; and the second extracted relevant profiles utilizing CNN.<sup>27</sup> Finally, using support vector machine, 87.2% accuracy was achieved in BC estimation from mammograms.<sup>27</sup> Another study also presented a CAD system for BC detection from MG images.<sup>24</sup> Their method manipulated MG images for ROI identification, relevant profile extraction and optimization, and BC stratification using a specific ML algorithm, SVM.<sup>24</sup> Based on their results, the aforementioned approach exhibited strong efficacy, particularly in distinguishing between normal and abnormal tumours with 100% accuracy.24 Lastly, researchers employed an integrated regression learning, SVM and MLP system to stratify mammograms.<sup>28</sup> They yielded 99.42% accuracy with the Wisconsin Breast Cancer Dataset.<sup>28</sup> This current review extracted and organized the data in tabular form and summarized the use of MG in the diagnosis of breast cancer (Table 1). 2,4,5,7,9,24,29–79

 Table I. Models, classes and performance for breast X-ray mammography data in selected papers. 2.4.5.7.9.24.29-79

			/l0 /			
Paper		Binary or			Other performance	
reference	Models/algorithm	multiclass	Classes	Accuracy	evaluation parameters	Anomaly application/task
29	LIBSVM	Binary	Positive/negative	ı	AUC = $0.725 \pm 0.018$	BC risk detection
30	SVM	Binary	Malignant/benign	99.385%	Sensitivity = $100\%$	BC detection
3		:	:		specificity = 78.785%	-
- 6	SVM, ELM	Multiclass	Normal/benign/malignant	94.11%	I	BC detection
32	DL, SAE	Binary	Malignant/benign	89.7%	AUC = 0.90	BC detection
33	NNAb	Binary	Malignant/benign	0.81	AUC = 0.85	BC detection
34	DCNN	Binary	Malignant/benign	0.85	AUC = 0.84	BC detection
35	DNN	Binary	Malignant/benign	ı	1	BC tumour detection
36	SVM, LASSO, KNN,	Binary	Malignant/benign	0.738	Sensitivity $= 0.957$	BC tumour detection
	B:SWIMS					
37	SVM	Binary	Malignant/benign	06.0	ROC = 0.95	BC tumour detection
38	SVM, KNN, LDA	Binary	Malignant/benign	0.80	Specificity $=$ 0.94 $\pm$ 0.06	BC diagnosis
		•	,		Sensitivity $=$ 0.66 $\pm$ 0.24	,
7	RF	Binary	Malignant/benign	0.93	Sensitivity $= 0.91$	BC tumour detection
					Accuracy = 0.82	
4	SVM, KNN, LR	Binary	Malignant/benign	0.978, 0.975	Specificity $= 0.975$	BC diagnosis
					Sensitivity $= 0.983$	
39	RF	Binary	Normal/tumour	19:0	Sensitivity $=$ 70%	BC risk outcome
					Specificity $= 49\%$	
40	CNN, VGG16,	Binary	Normal/cancer	0.98	Specificity $= 0.91$	BC tumour detection
;	residual network				Sensitivity $= 0.87$	
4	Faster R-CNN	Binary	Lesion/non-lesion	ı	ı	BC tumour detection
!			Malignant/benign			
42	SVM, VGGI6, CNN	Binary	Malignant/benign	0.88	AUC = 0.88	BC image classification
5	SVM, RF, NB	Binary	Malignant/benign	0.72	AUC = 0.79	BC image classification
43	DCNN	Binary	Malignant/benign	ı	1	BC image classification
;						BC diagnosis
4 ;	Faster R-CNN30, CNN	Binary	Malignant/benign	0.94	Specificity 0.92	Cancer subtype classification
45	N N N	Binary	Malignant/benign	0.92	AUC = 0.92	BC image classification
46	ANA	Binary	Malignant/benign	0.82	AUC = 0.83	Identify risk categories
						(bendiaco)

(continued)

Table I. Continued.

Paper		Binary or			Other performance	
reference	Models/algorithm	multiclass	Classes	Accuracy	evaluation parameters	Anomaly application/task
47	VGG16, SVM, KNN, NB, DT	Binary	Malignant/benign	66.0	Specificity $= 0.98$	BC tumour detection
48	SVM	Binary	Malignant/benign	0.82	AUC = 0.80	BC tumour detection
	DCNN, VGG19	Binary	Malignant/benign	0.99	Specificity $= 1.00$	BC image classification
	DCNN	Binary	Malignant/benign	080	ROC 0.84	BC tumour detection
20	RF	Multiclass	Normal/benign/malignant	0.85	F-score 0.98	BC tumour detection
						and classification
51	SVM, QGA	ı	I	ı	I	BC tumour edge detection
52	DNN, AlexNet,	Binary	Malignant/benign	0.987	Specificity = 0.99	BC classification
	VGGNet				Sensitivity $= 0.99$	
53	RBFNN	Binary	Malignant/benign	0.98	Sensitivity $= 0.98$	Breast microcalcifications
						early diagnosing
54	DCNN	Binary	Malignant/benign	ı	AUC = 0.91	Breast mass classification
55	ANA	Binary	Malignant/benign	ı	Specificity $= 0.94$	BC screening and diagnosis
26	ANN, SVM	Binary	Malignant/benign	0.99	Specificity = 0.99	BC tumour detection
		,			Sensitivity $= 0.99$	
24	SRG, SVM	Binary	Malignant/benign	0.87	Specificity = 0.86	BC tumour detection
					Sensitivity $= 0.90$	
57	SVM, NSEA	Multiclass	BI-RADS classification	0.94	$Time = 0.68 \; s$	BC diagnosis
28	MOD-RES	Binary	Malignant/benign	0.89	F-score = 0.89	BC detection
59	DCNN	Binary	Malignant/benign	0.99	F-score = 0.99	BC detection
09	MK-SVM	Multiclass	Normal/malignant/benign	96.0	Precision = 0.94	BC image classification
19	Kernel-SVM	Binary	Malignant/benign	0.99	1	BC detection
62	SVM, ResNet50	Binary	Malignant/benign	0.74	AUC = 0.82	BC detection
63	MobileNet	Binary	Malignant/benign	98.0	Sensitivity $= 0.93$	BC detection
64	SCNN, DCNN	Binary	Malignant/benign	0.951	F-score = 0.957	BC diagnosis
65	IMPA-ResNet50	Binary	Malignant/benign	0.98	AUC = 0.9788	BC diagnosis
99	ResNet50	Binary	Malignant/benign	ı	$AUC = 0.866 \pm 0.015$	Breast lesion classification
29	SVM, KNN, DT, LDA	Binary	Malignant/benign	0.963	Sensitivity $= 94.1\%$	BC detection
					Specificity $=$ 98.2%	

(continued)

Table 1. Continued.

Paper reference	Paper reference Models/algorithm	Binary or multiclass	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
89	SqueezeNet, FSVM	Binary	Malignant/benign	0.98	F-score = 97.87%	BC detection and
69	EDNN, MSVM	Multiclass	Normal/benign/malignant	96.72%	Recall = 96.24%	classification BC detection
70	SVM, DT, RF, NB	Binary	Malignant/benign	0.99	1	BC detection
71	2D V-net 64 CNN	Binary	Malignant/benign	0.98	Sensitivity $= 0.96$	BC detection
					Specificity = 0.96	
22	AlexNet, VGG, GoogleNet CNNs	Binary	Malignant/benign	%08.86	Sensitivity $= 99.62\%$	Breast lesion diagnosis
73	LASSO regression	Binary	Malignant/benign	ı	AUC = 0.940	BC diagnosis
74	ANN	Binary	Malignant/benign	%00 I	Specificity $= 100\%$	BC classification
					Sensitivity $= 100\%$	
75	Classification ML	Binary	Cancer or non-cancer	ı	Sensitivity $= 100\%$	BC diagnosis
76	LR	Binary	Negative and positive	ı	AUC = 0.742	BC ALN detection
					Sensitivity $= 0.783$	
					Specificity = 0.630	
77	VGG16, SVM	Binary	Malignant/benign	ı	$AUC = 0.876 \pm 0.031$	BC detection
6	Mask RCNN	Binary	Malignant/benign	ı	AUC = 0.89	Breast AD diagnosis
					Sensitivity $= 0.93$	
78	ONN, CCNN	Binary	Malignant/benign	ı		BC detection
79	DT, ANN	Binary	Malignant/benign	83%	Sensitivity $=$ 95%	Breast microcalcification
						diagnosis

extraction algorithm; MOD-RES, modified version of residual network 50; MK-SVM, multi-kernel support vector machine; ResNet 50, residual network 50; MobileNet, mobile network; SCNN, shallow convolutional neural network; IMPA, improved marine predators algorithm; SqueezeNet, squeeze network; FSVM, fuzzy support vector machine; EDNN, ensemble deep neural network; MSVM, multiclass support vector machine; CNNs, convolutional neural networks; ML, machine learning; ALN, axillary lymph node; east absolute shrinkage and selection operator; KNN, k-nearest neighbour; B:SWIMS, bootstrapped stagewise model selection; ROC, receiver operating characteristic; LDA, LIBSVM, a library for support vector machines; AUC, area under the curve; BC, breast cancer; SVM, support vector machine; ELM, extreme learning machines; DL, deep earning; SAE, stacked autoencoder; dANN, deep learning with artificial neural network; DCNN, deep convolutional network; DNN, deep neural network; LASSO convolutional neural network; NB, naïve Bayes; ANN, artificial neural network; DT, decision tree; VGG19, visual geometry group 19; QGA, quantum genetic algorithm; inear discriminant analysis; RF, random forests; LR, logistic regression; CNN, convolutional neural network; VGG16, visual geometry group 16; R-CNN, region-based AlexNet, Alex network; VGGNet, visual geometry group network; RBFNN, radial basis function neural network; SRG, seeded region growing; NSEA, novel spectral AD, architectural distortion; QNN, quantum neural network; CCNN, classical convolutional neural network.

# Ultrasonography

Ultrasonography is most frequently imaging technique used to screen for earlystage BC. US images are typically preferred as they, unlike MG, are not associated with radiation or compression. Nevertheless, its SEN is similar to digital MG (DM) and multiple studies confirmed its enhanced identification of invasive and nodenegative BC.80,81 Breast US (BUS) images are known to reliably delineate between b-BT and m-BT in five distinct areas, namely, shape, orientation, margin, echo patterns and posterior acoustic profiles.82 Despite the aforementioned advantages, US images can have some major shortcomings, namely, reduced resolution, contrast and blurred edges owing to noise originating from speckle and acoustic shadowing. Therefore, elucidation and BC identification from BUS is often challenging and operator dependent. CAD systems are an alternative automated approach for BC classification and it minimizes dependency on the operator.<sup>83</sup> BUS SEN and SPC can potentially be further augmented using ML. ML serves as a second reader that assists radiologists in forming a diagnosis.<sup>84,85</sup> ML algorithms study profiles of known cases to generate models that accurately diagnose patients with undetermined diseases. LR and naïve Bayes are two such programs with distinct learning capacities, and they show similar BC diagnosis on sonographic images.<sup>86</sup> These programs were integrated to generate an augmented model, which was grayscale profile-trained only with serial adaptive boosting.84 Rather than boosting homogenous weak learner like canonical AdaBoost, the integrated program boosts heterogeneous classifiers like naïve Bayes and LR which have established performances, and which closely agree on individual cases.84-86

Given that the BUS and elastography ultrasound (EUS) integration automatically

provides more data for BC diagnosis, the bimodal US-based CAD has generated much attention in recent times. A previous study reported the application of a deep polynomial network on dual modal BUS and EUS properties to delineate between m-BT and b-BT tumours.<sup>87</sup> Another study also employed pretrained bi-channel CNNs to study and integrate bimodal US image profiles for BC tumour detection.<sup>88</sup> Although the aforementioned studies indicate a strong efficacy of bimodal tools, the single-mode BUS-derived CAD offers more flexibility and broader application, and its performance can be further enhanced with transfer learning using EUS as the source domain.

Artificial intelligence, composed of ML and brain-inspired DL neural networks, have great potential in combating current challenges within the global healthcare system. Recent AI applications in medical US images include numerous specific tasks, such as image segmentation and biometric measurement.<sup>8</sup> Prior investigations successfully established tools for automated BT segmentation as well as CAD US intranodal vascularity quantification.<sup>89</sup> AI complements radiomics, which is used to extract meaningful imaging information, such as textural and wavelet data, which cannot otherwise be acquired by humans. Using the aforementioned radiomics profiles, one can train AI to conduct its own diagnosis, for example, stratifying a tumour as b-BT or m-BT. The precise identification of b-BT or m-BT from US imaging is critical for the timely intervention of BC patients. Moreover, effective decision support systems can markedly enhance radiological diagnostic ability.

A retrospective investigation evaluated US imaging and clinical information from 140 surgically confirmed BC cases. <sup>90</sup> In particular, the study examined twelve US and colour Doppler images using ML tools, among which eight profiles were statistically different between the two images (P < 0.05). <sup>90</sup> The final diagnostic exhibited

an AUC of 0.88, SEN of 86.96% and SPC of 82.91%. 90 Another study established an automated BC diagnostic system with enhanced precision that could be readily run on smartphones.<sup>91</sup> Upon US report entry, the program automatically analyses and detects lesions from all uploaded images. 91 The aforementioned process consists of three subsystems.<sup>91</sup> Firstly, noise is minimized within the images, followed by reconstruction of high-quality the images. 91 Subsequently, the initial subsystem is generated based on a stacked denoising autoencoder framework and generative adversarial network. 91 Then, the image is stratified according to malignancy or nonmalignancy. 91 DCCN is used to isolate significant profiles from the image. 91 Lastly. system performance anomalies are examined and eliminated, which further diminishes the false negative rate.<sup>91</sup> The current review extracted and organized the data in tabular form and summarized the application of US images in breast cancer diagnosis (Table 2). 6,8,80,83,90,92–118

## MRI

Breast MRI is frequently employed for the presurgical assessment of malignancy status, as well as the identification of potential ipsi- or contralateral BT. MRIidentified surplus BTs are BTs detected on presurgical MRI, which were undetected in prior MG or US. A secondary or targeted US is typically conducted to further assess the surplus BT. But, US is generally nonspecific for malignant tissue identification, and the MRI and US association rates are often widely variable between 23%-89%, based on multiple factors, including, radiologist performance or patient-specific differences. 119

Researchers utilized deep transfer learning CAD-based diagnosis to identify BC. <sup>120</sup> In particular, they used multi-parametric MRI (mpMRI) relative to a simple

independent CAD. 120 They demonstrated that the mpMRI tool provided superior results in delineating b-BT from m-BT; and the dynamic contrast-enhanced (DCE) image precision was 85%. 120 Nevertheless, there are certain limitations to this method. 120 Another study utilized 4-dimensional MRI by recording the maximum intensity projection from two distinct data, namely, image and feature, within a CNN via SVM classifier. 121 Based on their analysis, the image level exhibited a 91% precision, whereas, the feature level achieved a 93% accuracy. 121 However, their dataset was not generalized and did not include clinically sound information. 121

A multiparametric radiomics model combining DCE- and diffusion-weighted imaging-extracted profiles revealed an optimal AUC (0.85; 95% confidence interval, 0.77, 0.92) and diagnostic precision (81.7%; confidence interval, 73.0, 88.6). 122 Therefore, radiomics analysis combined with multiparametric MRI ML provides an enhanced assessment of suspicious augmenting breast tumours that are indicated for biopsy on clinical breast MRI. 122 This facilitates highly precise BC detection while minimizing needless b-BT biopsies. 122

Newly developed imaging techniques, such as US, MG, computed tomography (CT), PET and MRI are frequently employed for early BC detection. Among them, however, MRI ranks first in terms of patient prognosis, diagnostic precision, staging and presurgical planning. Furthermore. MRI also exhibits enhanced SEN than MG; and MRI diagnostic results are only minimally impacted by breast density. Hence, MRI is regarded as an essential tool for BC clinical diagnosis. 123 A previous investigation achieved an AUC of 0.654 via an ML model that analysed MRI images to delineate between triple-negative breast cancer and remaining subtypes. 124 The current review extracted and organized the data in tabular form and summarized the

 Table 2.
 Models, classes and performance for breast ultrasound image data in selected papers. 6.8.80,83.90,92-118

Paper reference	Models/algorithm	Binary or multiclass	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
92	ML, SL	Binary	Malignant/benign	0.957	Sensitivity $= 0.912$	BC diagnosis
83	BPANN, SVM	Binary	Malignant/benign	$98.966\% \pm 0.527$	Specificity $=$ 0.368 $\pm$ 0.473 AUC $=$ 98.976% $\pm$ 0.473	Breast tumour
80	ΔL	Binary	Malignant/benign	1	AUC = 0.86	classification BC diagnosis
93	DFCN, CNN, SVM	Binary	Malignant/benign	71.9%	AUC = 0.795	BC detection
94	SVM	Multiclass	Normal/benign/malignant	94.4%	AUC = 0.98	BC detection and
						classification
06	ML	Binary	TN subtype/	I	AUC = 0.88	BC subtypes
			nTN subtype		Sensitivity $=$ 86.96%	
					Specificity $=$ 82.91%	
95	FK, FS, FB, KS, KB, SB	Binary	Malignant/benign	ı	$\kappa \approx$ 0.944	BC detection
98	ML	Binary	Malignant/benign	ı	$ROC = 0.958 \pm 0.013$	BC detection
96	UND	Binary	Malignant/benign		AUC = 0.9468	BC detection
					Sensitivity $= 0.88$	
					Specificity $= 0.876$	
26	HSIC, SVM, DSPTC	Binary	Malignant/benign	$91.44 \pm 1.51\%$	Sensitivity $=$ 90.29 $\pm$ 3.17%	BC detection
					Specificity $=$ 92.65 $\pm$ 5.06% At IC $=$ 0.946	
86	LR, RF, SV, XGBoost	Binary	Malignant/benign	82.1%	AUC = 0.906	BC diagnosis
66	∐		)			BC diagnosis
001	RF, LR, SVM,	Binary	Malignant/benign	0.974	AUC = 0.97	Breast tumour
	AdaBoost, DT				$FI ext{-score} = 0.94$	classification
ω	RF, CNN	Binary	Malignant/benign	%98	Sensitivity = 84%	Breast lesion
					${\sf Specificity} = {\sf 88\%}$	classification
					$FI ext{-score} = 0.83$	
9	DONN	Binary	Malignant/benign	86.5%	AUC = 0.875	BC classification
					Sensitivity $=$ 86.6%	
					Specificity $=$ 87.1%	

(continued)

	•
τ	)
ď	)
Ξ	3
5	
Œ	5
È	
c	)
Ċ	١
_	•
_	i
~	Į
٩	)
7	5
'n	j
_	

Paper reference	Models/algorithm	Binary or multiclass	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
101	SVM	Binary	Malignant/benign	0.939 ± 0.039	Sensitivity $= 0.922 \pm 0.045$	BC detection
102	SVM		Malignant/benign	%0.98	AUC = 0.885	Breast lesion
103	DCNN	Binary	Malignant/benign	93.53%	Sensitivity $=$ 94.42 %	Glassification Breast lesion
<u> 1</u> 01	XGBoost, RF, SVM	Binary	Malignant/benign	88.4%	Specificity= 90.75 % Sensitivity = 90.3%	classification BC diagnosis
					Specificity = 86.7% AUC = $0.890$	
105	DCNN	Multiclass	Subclasses	I	ı	BC subtype identification
901	NB, SVM	Binary	Malignant/benign	89.17%	AUC = 0.95	Breast tumour
107	XNX	Binary	Malignant/benign	70.00%	Sensitivity $=$ 70.00%	BC detection and
					Specificity $=$ 70.83%	classification
801	ONN	Binary	Malignant/benign	0.8186	Sensitivity = $0.8095$	BC diagnosis
601	LR, DT, RF, Bagging	Binary	DCIS, IDC	ı	Specificity = $0.8265$ AUC = $0.66-0.78$	BC diagnosis
0110	NN, LR	Binary	Malignant/benign		AUC = 0.93	BC diagnosis
:					Sensitivity $=$ 100.0%	
≣	Z	Binary	Negative/positive	89.72%	Sensitivity = $84.00\%$ Specificity = $94.74\%$	BC LN detection
112	CKHA, VGG-16,	Multiclass	Malignant/benign/	%60'26	Sensitivity $=$ 95.54%	BC Diagnosis and
:	VGG-19, SqueezeNet		normal		Specificity $=$ 97.65%	classification
5	LR, SVM	Multiclass	BI-RADS category 4A/4B/4C	1	AUC = 0.908	BI-RADS 4 lesion screening
4	DNN, RF	Binary	Malignant/benign	78.5%	I	BC diagnosis
115	DNN, SVA	Binary	Malignant/benign	87.1% ± 3.3%	Sensitivity $=$ 77.4% $\pm$ 11.8% Specificity $=$ 92.4% $\pm$ 7.2%	BC diagnosis

(continued)

	3		
•	4		
(			
•		•	
:	(	1	L
•			

Paper reference	Paper eference Models/algorithm	Binary or multiclass Classes	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
116	SVM, XGBoost, RF, LR, NB, KNN, MLP, CNN,	Binary	Negative/positive	168.0	AUC = 0.952 Kappa = 0.763	BC SLN detection
117	XGBoost, CNN, ResNet DL, ML	Binary Binary	Malignant∕benign Malignant∕benign	1 1	AUC = 0.84	BC detection BC detection

forests; SV, support vector; XG Boost, extreme gradient boosting; Adaboost, adaptive boosting; DT, decision tree; DCNN, deep convolutional neural networks; NB, naïve receiver operating characteristic; HSIC, Hilbert-Schmidt Independence Criterion; DSPTC, doubly supervised parameter transfer classifier; LR, logistic regression; RF, random Bayes; KNN, k-nearest neighbour; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; NN, neural network; PNN, probabilistic neural network; LN, lymph node; reporting and data system; DNN, deep neural network; MLP, multilayer perceptron; LSTM, long short-term memory; LDA, linear discriminant analysis; SLN, sentinel lymph iorest-stochastic gradient; FB, forest-naïve Bayes; KS, k-nearest neighbour-stochastic gradient; KB, k-nearest neighbour-naïve Bayes; SB, stochastic gradient-naïve Bayes; ROC, ML, machine learning; SL, supervised learning; BC, breast cancer; BPANN, back-propagation artificial neural network; SVM, support vector machine; AUC, area under the curve; DFCN, dilated fully convolutional network; CNN, convolutional neural networks; TN, triple-negative; nTN, non-triple-negative; FK, forest-k-nearest neighbour; FS, SqueezeNet, squeeze network; BI-RADS, breast imaging-CKHA, chaotic krill herd algorithm; VGG-16, visual geometry group-16; VGG-19, visual geometry group-19; ResNet, residual network; DL, deep learning. application of MRI in breast cancer diagnosis (Table 3). 109,119,120,123,125–166

## Others

X-ray mammography is often employed for BC identification. However, it is a highly invasive procedure because X-rays damage tissues and quite frequently fails to determine the tumour size. Lately, thermography has emerged as a safer non-invasive approach, with no contact imaging. This process does not involve ionizing radiation, venous access or other invasive protocols. Thermography used human body-emitted infrared electromagnetic radiation that is picked up by a thermographic camera for analysis by a CAD system. However, for widespread application, it is imperative to enhance the accuracy of these new tools. ML has successfully enhanced diagnostic precision while minimizing the presence of false positives and false negatives while analysing breast thermograms.

Various forms of research have examined thermography-based BC identification. This current review will present recent significant publications. A study published in 2023 reported a new AI- and thermography-based CAD system that assists radiologists in accurately diagnosing breast diseases. 167 The procedure for this new tool is as follows: using the U-net model, an intersection over an 89.03% union is achieved. 167 The segmented thermograms then undergo textural assessment and vascular network analysis to isolate sigprofiles. 167 Subsequently, implementation of the supervised learning algorithm-based classifiers and usage of the retrieved profiles, the normal versus abnormal thermograms are identified. 167 This process of BC identification was further confirmed as highly effective, revealing optimal stratification while using SVM, with a 94.4% accuracy, 96.2% precision, 86.7% recall, 91.2% F1-score and 98.3%

 Table 3.
 Models, classes and performance for breast magnetic resonance imaging data in selected papers.
 109,119,120,123,125-166

Paper reference	Models/algorithm	Binary or multiclass	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
125	ML SVM DT	Binary	Malignant/benign	81.5%	Specificity = 91.4% ROC = 91.1%	BC detection RC additional
		<b>/</b>	ı alığılalıy ocuşlı	8		lesion detection
122	SVM	Binary	Malignant/benign	81.7%	AUC = 0.85	BC detection
126	SVM, KNN, RF	Binary	Malignant/benign	78.50	AUC = 78.50	BC diagnosis
					Sensitivity $=$ 0.923	
					Specificity $= 0.722$	
127	SVM, LR, NB, KNN	Binary	Malignant/benign	0.93	Sensitivity $=$ 0.85	BC diagnosis
					Specificity = 0.89	
					AUC = 90.9%	
128	LR	Binary	Malignant/benign	I	AUC = 95.25	BC diagnosis
123	SVM-RFE, RUSBoost	Binary	Malignant/benign	I	AUC = 0.9617	BC diagnosis
129	DCNN, VGGNet	Binary	Malignant/benign		AUC = 0.88	Breast lesion classification
130	RF	Binary	Malignant/benign	I	ROC = 0.852	Breast lesions classification
131	DT	Binary	3+IHC/FISH+	83.9%	Sensitivity $=$ 86.5%	HER2 expression level
					${\sf Specificity} = {\sf 80.0\%}$	
132	SVM, Bayes, KNN,	Binary	PCR/nonPCR	I	AUC = 0.879	BC NACT Efficacy
	RF, DT				Specificity = 82.19%	
					Sensitivity $=$ 83.57%	
133	RF, LR, NB	Multiclass	Luminal A/luminal B/	ı	AUC = 0.75	BC phenotype
			HER2-enriched/			
;			triple-negative			
134	SVM	Binary	Malignant/benign	74.1%	$AUC = 0.77 \pm 0.06$	BC diagnosis
120	CNN, SVM	Binary	Malignant/benign	ı	AUC = 0.87	BC diagnosis
135	SVM	Binary	Malignant/benign	I	AUC = 0.87	BC diagnosis
136	SVM	Binary	Malignant/benign	I	AUC = 0.925	BC diagnosis
137	IsoSVM	Binary	Malignant/benign	I	Sensitivity $=$ 82.5%	BC detection
					${\sf Specificity} = {\sf 80.5\%}$	
					AUC = 0.87	

(continued)

Table 3. Continued.

multiclass         Classes         Accuracy         evaluation parameters           Binary         Malignant/benign         98.97 ± 0.13         Sensitivity = 96.20 ± 0.82           Multiclass         TP/FP/negative         -         AUC = 0.50-0.53           A,         Multiclass         Malignant/benign         83.67%         -           A,         HER2+TTNBC         88.2%         Sensitivity = 96.5%           Binary         Malignant/benign         94.1%         Sensitivity = 90.7%           Binary         PD-L1+/ PD-L1-         88.2%         Sensitivity = 90.7%           Binary         PD-L1+/ PD-L1-         88.2%         Sensitivity = 90.7%           Binary         Malignant/benign         -         AUC = 0.91-0.98           Binary         Malignant/benign         -         AUC = 0.85           Binary         Malignant/benign         -         Sensitivity = 90.0%           Binary         Malignant/benign         -         Sensitivity = 95.3%           Binary         Malignant/benign         -         AUC = 0.90           Binary         Malignant/benign         -         AUC = 0.90           Binary         Malignant/benign         -         AUC = 0.90           Binary         Malignant/b	Paper		Binary or			Other performance	Anomaly
U-Net CNN         Binary         Malignant/benign         98.97 ± 0.13         Sensitivity = 96.20 ± 0.82           LR, ML         Multiclass         TP/FP/negative         -         AUC = 0.50-0.53           DCNN, AdaBoost         Multiclass         Malignant/benign/normal         97.2%         Sensitivity = 96.5%           KNN, DT, NB, RF, SVM         Binary         Multiclass         HRP4-HFR2-/INBC         0.735         AUC = 0.896           SVM, MLP         Binary         PD-L1+/PD-L1-         88.2%         Sensitivity = 90.7%           LR, SVM, RF         Binary         Complete responders         -         AUC = 0.91-0.98           KNN, RF         Binary         Malignant/benign         -         AUC = 0.85           SVM         ML         Binary         Malignant/benign         -         AUC = 0.85           SVM         ML         Binary         Malignant/benign         -         Sensitivity = 80.0%           SVM         ML         Binary         Malignant/benign         -         AUC = 0.85           SVM         LDA, SVM         Binary         Malignant/benign         -         AUC = 0.90           SVM         Binary         Malignant/benign         -         AUC = 0.90           SVM         Bin	reference	Models/algorithm	multiclass	Classes	Accuracy	evaluation parameters	application/task
LR, ML  DCNN, AdaBoost Multiclass TP/FP/negative – AUC = 0.50–0.53  DCNN, AdaBoost Multiclass Malignant/benign   97.2% Sensitivity = 98.3% Specificity = 96.5%    KNN, DT, NB, RF, SVM Binary Malignant/benign   83.67% – AUC = 0.896  SVM, MLP  DT  Binary Malignant/benign – AUC = 0.91–0.98  Non-complete responders   AUC = 0.91–0.98  Non-complete responders   AUC = 0.91–0.98  KNN, RF  Binary Malignant/benign – AUC = 0.85  SVM Malignant/benign – AUC = 0.88  SVM Malignant/benign – AUC = 0.89  SVM Malignant/benign – AUC = 0.90  SVM AUC = 0.90  SVM AUC = 0.90  SVM AUC = 0.90  SVM AUC = 0.90	138	U-Net CNN	Binary	Malignant/benign	$98.97 \pm 0.13$	Sensitivity $=$ 96.20 $\pm$ 0.82 Specificity $=$ 99.54 $\pm$ 0.10	BC detection
DCNN, AdaBoostMulticlassMalignant/benign/normal97.2%Sensitivity = 98.3%KNN, DT, NB, RF, SVMBinaryMalignant/benign83.67%SVM, MLPBinaryHRR2+TTNBC88.2%Sensitivity = 90.7%DTBinaryPD-L1+/PD-L1-88.2%Sensitivity = 90.7%LR, SVM, RFBinaryComplete responders-AUC = 0.91-0.98KNN, RFBinaryMalignant/benign-AUC = 0.91-0.98RF, SVM, PCABinaryMalignant/benign-AUC = 0.85SVMBinaryMalignant/benign-Sensitivity = 80.0%SVMBinaryMalignant/benign-Sensitivity = 80.0%SVMBinaryMalignant/benign-Sensitivity = 95.3%SVMBinaryMalignant/benign-AUC = 0.88SVMBinaryMalignant/benign-AUC = 0.90SVMBinaryMalignant/benign-AUC = 0.90SVMBinaryMalignant/benign-AUC = 0.75ResNet50,Powerseponse-AUC = 0.90Inception-ResNet-20,PAM50 subtypesAUC = 0.90Inception-ResNet-20,PAM50 subtypesAUC = 0.90SVMMalignant/benign-AUC = 0.90Inception-ResNet-20,PAM50 subtypesAUC = 0.90Inception-ResNet-20,PAM50 subtypesAUC = 0.90	139	LR, ML	Multiclass	TP/FP/negative	1	AUC = 0.50-0.53	Preoperative
DCNN, AdaBoost Multiclass Malignant/benign/inormal 97.2% Sensitivity = 98.3% Specificity = 96.5% AUC = 0.896  RF, LR, GNB, LDA, Multiclass HR+/HER2—/ 0.735 AUC = 0.896  SVM, MLP Binary PD-L1+/ PD-L1— 88.2% Sensitivity = 90.7% Specificity = 85.1% AUC = 0.91–0.98  ILR, SVM, RF Binary Complete responders/ — AUC = 0.91–0.98  RF, SVM, RF Binary Malignant/benign — AUC = 0.91–0.98  RF, SVM, NB, LDA, LR Binary Malignant/benign = Sensitivity = 99.0% SVM Malignant/benign = Sensitivity = 95.3% Specificity = 87.8% AUC = 0.90  SVM Binary Malignant/benign = Sensitivity = 95.3% Specificity = 71.2% AUC = 0.90  SVM Binary Malignant/benign = Sensitivity = 95.3% SVM Binary Malignant/benign = AUC = 0.90  ResNet50, AUC = 0.94  AUC = 0.95  AUC = 0.90	140	:	:				Breast detection
KNN, DT, NB, RF, SVM Binary Malignant/benign 83.67% –  RF, LR, GNB, LDA, Multiclass HR+HFR2-/ SVM, MLP Binary PD-L1+/PD-L1- 88.2% Sensitivity = 90.7% Specificity = 85.1% non-complete responders non-complete responders halfgrant/benign PALS Specificity = 87.8% SVM Malignant/benign PALS Somsitivity = 99.0% SVM Binary Malignant/benign PALS Specificity = 87.3% Somsitivity = 95.3% SVM Malignant/benign PALS Somsitivity = 95.3% Specificity = 71.2% LDA, SVM Binary Malignant/benign PALC = 0.90 SVM Binary Poor response AUC = 0.90 SVM Binary Poor response AUC = 0.90 SVM Binary Palignant/benign PAMS0 subtypes AUC = 0.90 Inception-v3, VGG-16, Multiclass ER-4+PR-4+ AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary Malignant/benign Binary PAMS0 subtypes AUC = 0.90 Inception-ResNet-v2 Binary PAMS0 subtypes AUC = 0.90 Binary PAMS0 subtypes Binary PAMS0 subt	2	DCNN, AdaBoost	Multiclass	Malignant/benign/normal	97.2%	Sensitivity = $98.3\%$ Specificity = $96.5\%$	BC detection
RF, LR, GNB, LDA, Multiclass HR+/HER2—/ 0.735 AUC = 0.896  SVM, MLP  Binary PD-L1+/ PD-L1— 88.2% Sensitivity = 90.7% Specificity = 85.1%  LR, SVM, RF  Binary Complete responders/ — AUC = 0.91—0.98  non-complete responders — AUC = 0.91—0.98  RF, SVM, PCA Binary Malignant/benign — AUC = 0.85  SVM  Binary Malignant/benign — Sensitivity = 85.3% Sensitivity = 95.3%  LogitBoost, RF  Binary Malignant/benign — Sensitivity = 95.3%  SVM  LDA, SVM  Binary Malignant/benign — Sensitivity = 95.3%  SVM  Binary Malignant/benign — AUC = 0.98  SVM  Binary Malignant/benign — AUC = 0.90  SVM  Binary Malignant/benign — AUC = 0.90  SVM  Binary Poor response/ — AUC = 0.90  ResNet50, PAMSO subtypes  Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ — AUC = 0.90  ResNet50, PAMSO subtypes  Inception-ResNet-v2  SVM  Binary Malignant/benign — AUC = 0.942  ResNet50, AUC = 0.906  SVM  Binary Malignant/benign — AUC = 0.906  SVM  Binary Malignant/benign — AUC = 0.906  SVM  Binary Malignant/benign — AUC = 0.906  ResNet50, AUC = 0.906	<del>-</del> 4	KNN, DT, NB, RF, SVM	Binary	Malignant/benign	83.67%		BC diagnosis
DT.  DT.  DT.  DT.  DT.  DT.  DT.  DT.	142	RF, LR, GNB, LDA, SVM, MIP	Multiclass	HR+/HER2-/ HFR2+/TNBC	0.735	AUC = 0.896	BC subtype identification
LR, SVM, RF Binary Complete responders/ - AUC=0.91-0.98  non-complete responders  KNN, RF Binary Malignant/benign - AUC=0.91-0.98  RF, SVM, PCA Binary Malignant/benign - AUC=0.85  SVM Binary Malignant/benign - AUC=0.85  SVM Malignant/benign - Sensitivity = 80.0%  SVM Malignant/benign - Sensitivity = 95.3%  LDA, SVM Binary Malignant/benign 85.9% Sensitivity = 95.3%  LDA, SVM Binary Malignant/benign 0.84 AUC=0.98  SVM Binary Malignant/benign - AUC=0.90  SVM Binary Poor response/ - AUC=0.75  excellent response  Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ 0.742 AUC=0.92  ResNet50, POOR PAMSO subtypes  Inception-ResNet-v2  SVM Binary Malignant/benign 88.5% AUC=0.920	143	DT	Binary	PD-LI+/ PD-LI-	88.2%	Sensitivity $= 90.7\%$	BC PD-LI expression status
KNN, RF Binary Malignant/benign 94.1% Sensitivity = 99.0% Specificity = 87.8% AUC = 0.85 SVM Binary Malignant/benign - AUC = 0.85 SVM Binary Malignant/benign - Sensitivity = 80.0% SVM, NB, LDA, LR Binary Malignant/benign 85.9% Sensitivity = 95.3% SVM, NB, LDA, LR Binary Malignant/benign 85.9% Sensitivity = 95.3% SVM, NB, LDA, SVM Binary Malignant/benign 0.84 AUC = 0.88 SVM Binary Malignant/benign - AUC = 0.90 SVM Binary Poor response/ - AUC = 0.90 SVM Binary Poor response/ - AUC = 0.90 SVM Binary Poor response/ - AUC = 0.90 SVM Binary Poor seponse/ - AUC = 0	44	LR. SVM. RF	Binary	Complete responders/	ı	AUC = $0.91-0.98$	BC neoadiuvant
KNN, RF Binary Malignant/benign 94.1% Sensitivity = 99.0%  RF, SVM, PCA Binary Malignant/benign - AUC = 0.85  SVM Binary Malignant/benign - AUC = 0.85  SVM Binary Malignant/benign - Sensitivity = 80.0%  SVM, NB, LDA, LR Binary Malignant/benign 85.9% Sensitivity = 95.3%  LOA, SVM Binary Malignant/benign 0.84 AUC = 0.90  SVM Binary Malignant/benign - AUC = 0.90  SVM Binary Poor response/ - AUC = 0.75  excellent response				non-complete			chemotherapy response
KNN, RF Binary Malignant/benign 94.1% Sensitivity = 99.0% RF, SVM, PCA Binary Malignant/benign - AUC = 0.85 SVM Binary Malignant/benign - AUC = 0.85 SVM ML Binary Malignant/benign - Sensitivity = 80.0% SVM, NB, LDA, LR Binary Iuminal A/luminal B - Sensitivity = 95.3% SVM, NB, LDA, LR Binary Malignant/benign 85.9% Sensitivity = 95.3% SVM Binary Malignant/benign 0.84 AUC = 0.90 SVM Binary Malignant/benign - AUC = 0.90 SVM Binary Poor response Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ 0.742 AUC = 0.920 Inception-ResNet-v2 Binary Malignant/benign 88.5% AUC = 0.956 SVM Binary Malignant/benign 88.5% AUC = 0.950	176			responders			
RF, SVM, PCA Binary Malignant/benign – AUC = 0.85 SVM Binary Malignant/benign – BB	<del>.</del> 5	KNN, RF	Binary	Malignant/benign	94.1%	Sensitivity = $99.0\%$ Specificity = $87.8\%$	Breast tumour classification
SVM  Binary Malignant/benign  ML  Binary Malignant/benign  LogitBoost, RF  Binary Iuminal A/luminal B  SVM, NB, LDA, LR  Binary Malignant/benign  SVM  Binary Malignant/benign  Caccellent response  Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/  Res Net 50,  Res Net 50,  PAM50 subtypes  Inception-ResNet-v2  SVM  Binary Malignant/benign  Binary Maligna	146	RF, SVM, PCA	Binary	Malignant/benign	I	AUC = 0.85	BC diagnosis
ML LogitBoost, RF Binary Iuminal A/Iuminal B LogitBoost, RF Binary Iuminal A/Iuminal B SVM, NB, LDA, LR Binary Malignant/benign SVM Binary Malignant/benign SVM Binary Malignant/benign SVM Binary Poor response Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ ResNet50, Inception-ResNet-v2 SVM Binary Malignant/benign AUC = 0.90 BC AUC = 0.90 BC AUC = 0.91 BC AUC = 0.92 BC AUC = 0.92 BC BC BC AUC = 0.92 BC	147	SVM	Binary	Malignant/benign	83.2%	1	BC diagnosis
LogitBoost, RF Binary luminal A/luminal B – Sensitivity = 80.0% BK SVM, NB, LDA, LR Binary Malignant/benign 85.9% Sensitivity = 95.3% BK Specificity = 71.2% BK SVM Binary Malignant/benign – AUC = 0.88 BK SVM Binary Malignant/benign – AUC = 0.90 BK SVM Binary Poor response/ – AUC = 0.75 BK Excellent response oxcellent response oxcellent response oxcellent response oxcellent PAM50 subtypes BK AUC = 0.942 BK SVM Binary Malignant/benign 88.5% AUC = 0.920 BK SVM Binary Malignant/benign 88.5% AUC = 0.920 BK SVM Binary Malignant/benign 88.5% AUC = 0.956 BK BK SVM Binary Malignant/benign 88.5% AUC = 0.956 BK BK SVM BK	84	MΓ	Binary	Malignant/benign	1	1	BC diagnosis
SVM, NB, LDA, LR Binary Malignant/benign 85.9% Sensitivity = 95.3% BC Specificity = 71.2% EDA, SVM Binary Malignant/benign - AUC = 0.88 BC SVM Binary Malignant/benign - AUC = 0.90 BC SVM Binary Poor response/ - AUC = 0.75 BC Excellent response	149	LogitBoost, RF	Binary		ı	Sensitivity $=$ 80.0%	BC prognosis
LDA, SVM         Binary         Malignant/benign         0.84         AUC = 0.88         BC           SVM         Binary         Malignant/benign         -         AUC = 0.90         BC           SVM         Binary         Poor response/         -         AUC = 0.75         BC           Inception-v3, VGG-16,         Multiclass         ER-/+/PR-/+/         0.742         AUC = 0.92         BC           Res Net.50,         PAM50 subtypes         AUC = 0.920         Br           SVM         Binary         Malismant/benian         88.5%         AUC = 0.96         Br	150	SVM, NB, LDA, LR	Binary	Malignant/benign	82.9%	Sensitivity $=$ 95.3%	BC differential diagnosis
LDA, SVM         Binary         Malignant/benign         0.84         AUC = 0.88         BC           SVM         Binary         Malignant/benign         -         AUC = 0.90         BC           SVM         Binary         Poor response/         -         AUC = 0.75         BC           Inception-v3, VGG-16,         Multiclass         ER-/+/PR-/+/         0.742         AUC = 0.942         BC           Res Net 50,         PAM50 subtypes         AUC = 0.920         Br           SVM         Binary         Malismant/henian         88.5%         AUC = 0.96         Br						Specificity $= 71.2\%$	
SVM Binary Malignant/benign – AUC = 0.90 BC SVM Binary Poor response/ – AUC = 0.75 BC excellent response Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ PAM50 subtypes Inception-ResNet-v2 Inception-ResNet-v2 SVM Binary Malignant/benign 88.5% AUC = 0.90 Br	151	LDA, SVM	Binary	Malignant/benign	0.84	AUC = 0.88	BC detection
SVM Binary Poor response – AUC = 0.75 BC excellent response lnception-v3, VGG-16, Multiclass ER-/+/PR-/+/ 0.742 AUC = 0.920 Res Net-v2 Binary Malianant/henian 88.5% AUC = 0.96 Br	152	SVM	Binary	Malignant/benign	ı	AUC = 0.90	BC diagnosis
excellent response Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ ResNet50, PAM50 subtypes AUC = 0.920 Inception-ResNet-v2 SVM SVM Binary Malienant/henien 88.5% AUC = 0.96 Br	153	SVM	Binary	Poor response/	I	AUC = 0.75	BC neoadjuvant
Inception-v3, VGG-16, Multiclass ER-/+/PR-/+/ 0.742 AUC = 0.942 ResNet50, AUC = 0.920 Inception-ResNet-v2 SVM SVM Alignant/benian 88.5% AUC = 0.96				excellent response			chemotherapy Response
ResNet50, PAM50 subtypes AUC = 0.920 Inception-ResNet-v2 Binary Malignant/benian 88.5% AUC = 0.96	154	Inception-v3, VGG-16,	Multiclass	ER-/+/PR-/+/	0.742	AUC = 0.942	BC subtype identification
SVM Binary Malignant/henian 88.5% AUC = 0.96		ResNet50,		PAM50 subtypes		AUC = 0.920	
	155	SVM	Binary	Malignant/benign	88.5%	AUC = 0.96	Breast lesion diagnosis

(continued)

Table 3. Continued.

Paper reference	Paper reference Models/algorithm	Binary or multiclass	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
601	LR, DT, RF, Bagging CNN-SVM	Binary	DCIS/IDC Malignant/henign	95 28%	AUC = 0.66-0.78 AUC = 0.974	BC diagnosis BC classification
157	NNO	Binary	Normal/abnormal	88.02%	AUC = 0.880	BC LNM detection
158	SVM	Binary	Malignant/benign	ı	AUC = 0.983	BC diagnosis
159	NB, RF, AB, DT,	Binary	Low/high	ı	AUC = 0.79	BC Ki-67 and histological
	KNN, SVM, LDA, LR					grade detection
091	SVM, RF, XGB	Binary	Phyllodes tumours/	93.0%	AUC = 0.97	Breast lesion differential
			fibroadenomas		sensitivity $=$ 92.0%	diagnosis
					specificity $= 94.0\%$	
191	RF, DT, SVM	Binary	Malignant/benign	0.88	AUC = 0.95	BC diagnosis
162	VGG-16, KNN,	Binary	Negative/positive	ı	AUC = 0.90	BC LNM detection
	XGBoost, LightGBM					
163	RF	Binary	PCR/non-PCR	80.0%	AUC = 0.77	BC neoadjuvant
						chemotherapy Response
164	LR	Binary	Negative/positive	I	AUC = 0.76	BC recurrence detection
165	NB	Binary	Malignant/benign	%19	Sensitivity of 70%	BC diagnosis
					Specificity of 66%	
991	SVM, RF, DT, NB,	Binary	Negative/positive	0.82	AUC = 0.85	TNBC TP53 mutation status
	LR, LDA, MLP					

analysis of microarray 50; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; CNN-SVM, convolutional neural networks-support vector machine; LNM, lymph principal component analysis; VGG-16, visual geometry group-16; ResNet50, residual network 50; ER, oestrogen receptor; PR, progesterone receptor; PAM50, prediction network; IsoSVM, isomap support vector machines; U-Net, U-network; TP, true positive; FP, false positive; AdaBoost, adaptive boosting; GNB, Gaussian Naiwe Bayes; LDA, nearest neighbour; RF, random forests: LR, logistic regression; NB, naïve Bayes; SVM-RFE, support vector machine-based recursive feature elimination; RUSBoost, random inear discriminant analysis; MLP, multilayer perceptron; HR, hormone receptors; TNBC, triple negative breast cancer; PD-L1, programmed death receptor ligand 1; PCA, ML, machine learning; BC, breast cancer; SVM, support vector machine; DT, decision tree; ROC, receiver operating characteristic; AUC, area under the curve; KNN, kundersampling boosting; DCNN, deep convolutional neural networks; VGGNet, visual geometry group network; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; PCR, pathological complete response; NACT, neoadjuvant chemotherapy; CNN, convolutional neural node metastasis; AB, adaptive boosting; XGB, extreme gradient boosting; XGBoost, extreme gradient boosting; GBM, gradient boosting machine.

true negative rate. 167 Another study conducted a binary stratification of m-BT and b-BT using breast thermographic images. 168 authors employed 94  $(320 \times 240)$  with biopsy-confirmed diagnoses, among which, 60 exhibited m-BT and 34 exhibited b-BT. 168 The authors used three distinct image analytical namely, blinded screening mode (SBS), clinical assessment and ANN. 168 The first method provided a risk score ranging from 0 (minimum risk) to 7 (very high risk).168 The remaining methods yielded a binary result, identifying whether a given lesion was m-BT or b-BT. 168 The analyses revealed that the ANN method excelled over the others, with a 81.8% accuracy, relative to 66.7% for SBS and 71.4% for clinical analysis. 168 Another study reported using CNN that included data augmentation and a fine-tuning optimization algorithm and a an automatic BC diagnosis. 169 These received a 92% accuracy and demonstrated that data augmentation considerably enhanced tumour stratification in breast thermography, particularly when data were scarce. 169

Furthermore, among studies examining thermographic images for BC classification, one demonstrated exhibited an SEN of 0.812 and an SPC of 0.882.<sup>170</sup> Additionally, screening tomosynthesis also garnered much attention owing to its enhancement of cancer detection rates, along with diminished false positive rates.<sup>171</sup> Similarly, screen-identification study evaluated approaches for tomosynthetic singlereading versus double-reading mammograms, and demonstrated an 8.2 versus 6.3 cancer detection rate per 1000 screens. 172

Additionally, there is also BT identification using highly advanced microwave systems, which facilitate a much safer, nonionizing approach to delineate between healthy and non-healthy tissues, based on individual dielectric profiles. The present microwave breast imaging research can be categorized as follows: microwave tomography (MT) and ultra-wideband (UWB) radar techniques. MT utilizes antennas with a matching liquid, whereas UWB employs 60 antennas with a matching liquid.<sup>173</sup>

More recently, ML approaches have been extensively examined for detecting BTs. In addition, DL methods have also been extensively examined. Currently, for BT microwave imaging, ML and DL have been used to analyse microwave datasets from numerical simulations or phantoms measurements.<sup>174</sup> Research evaluated for the first-time cancer detection using UWB enhanced by ML and conventional breast examinations. 174 The authors demonstrated that the SVM quadratic kernel classified breast information with 98% precision. 174 The current review extracted and organized the data in tabular form and summarized the application of CT, breast thermal imaging, PET and microwave imaging technology in the diagnosis of breast cancer (Table 4). 92,109,147,149,151,167,174–187

### Conclusion

In conclusion, the use of ML techniques for BC imaging has the potential to improve the accuracy and efficiency of diagnosis, classification and prediction, improving patient outcomes and reducing healthcare costs. ML still has its limitations, both in terms of imaging and pathological diagnosis, and ML cannot make a diagnosis of untrained diseases. In addition, ML requires a large amount of training data support, but because of research confidentiality or patient privacy protection, the effectiveness, safety and universality of data are the key issues troubling the clinical application of ML. However, further research is needed to address the challenges and limitations of these techniques, and to develop standardized protocols and benchmarks for evaluating their performance.

**Table 4.** Models, classes and performance for breast thermographic techniques, positron emission tomography and other combined examination data in selected papers. 92,109,147,149,151,167,174-187

Paper reference	Relevant examinations	Models/algorithm	Binary or multiclass	Classes	Accuracy	Other performance evaluation parameters	Anomaly application/task
175	CBCT	RF, KNN, BPN, SVM	Binary	Malignant/benign	ı	AUC = 0.91 Sensitivity = 0.85	BC detection
176	PET	SVM	Binary	Malignant/benign	0.85	Specificity = 0.82 AUC = 0.89 Sensitivity = 0.94	BC diagnosis
177	PET PET	CNN, MLP LogitBoost, RF	Binary Binary	Malignant/benign Luminal A/Luminal B	1 1	Specificity = 0.77 AUC = 0.947 AUC = 75%	BC diagnosis BC subtypes
178	PET Thermography	MultiResUnet3D	Binary	Negative/positive Malionant/henion	0.8843	Sensitivity $= 88.0\%$ AUC $= 0.775$ AUC $= 0.9675$	BC NAC response
180	Microwave PS-OCT	RF SVM	Binary Multiclass	Malignant/benign Malignant/fibroadipose/	0.87		BC diagnosis Breast tissue types
174	UWB	MLP-NN, SVM, KNN	Binary	stroma Lesion-containing/	%86	Sensitivity $= 0.97$	Breast lesion
167	Thermography PAT	DNN, SVM SVM, AlexNet, GoogleNet	Binary Binary	lesion-free Normal/ abnormal Malignant/benign	94.4% 0.9118	Specificity = $0.99$ F1-score = $91.2\%$ AUC = $0.8143$ Sensitivity = $0.8571$	detection BC Detection BC diagnosis
183	DCE-MRI, MGs DCE-MRI, MG	RBFNN, KNN, SVM, RF SVM	Binary Binary	Malignant/benign Malignant/benign	- 83.3%		BC detection BC diagnosis
109	MG, US, MRI MG	LR, DT, RF, Bagging RF, SVM, LMT, NB, KNN	Binary Binary	DCIS/ IDC Malignant/benign	1 1		BC diagnosis BC detection
185	Pathological images	deep learning, CNN, InceptionResNetV2	Binary	Cancerous/ non-cancerous	%16	ı	BC risk detection
981	s Sn	XGBoost Tree, LR	Binary	Malignant/benign	I	AUC = 0.90	Breast masses
92	US	SL, ML	Binary	Malignant/benign	95.7%	Sensitivity = $100\%$ Sensitivity = $0.912$ Specificity = $0.966$	ciassification BC diagnosis
							(1

(continued)

Р
Φ
П
П
. <b>=</b>
0
( )
$\overline{}$
_
4.
4
_
e 4.
e 4.
e 4.
4
e 4.

Paper	Relevant		Binary or			Other performance	Anomaly
reference	eference examinations	Models/algorithm	multiclass Classes	Classes	Accuracy	Accuracy evaluation parameters application/task	application/task
187	X-rays, US, MI, PSOWNN PET FIT	PSOWNN	Multiclass	Multiclass Malignant/benign/	%9:86	Specificity = 98.8%	BC detection
151	CEM. DCE-MRI LDA.	LDA. SVM	Binary	Malignant/benign	0.84	AUC = 0.88	BC detection

earning; MI, microwave imaging; EIT, electrical impedance tomography; PSOWNN, particle swarm optimized wavelet neural network; CEM, contrast-enhanced mammography under the curve; BC, breast cancer; PET, positron emission tomography; CNN, convolutional neural network; MLP, multilayer perceptron; NAC, neoadjuvant chemotherapy DNN, deep neural network; PAT, photoacoustic tomography; DCE-MRI, dynamic contrast enhancement-magnetic resonance imaging; MGs, mammographic images; RBFNN gradient boosting; SL, supervised learning; ML, machine PS-OCT, polarization-sensitive optical coherence tomography; UWB, ultra-wideband; MLP-NN, multi-layer perceptron neural network; radial basis function neural network; MG, mammography; US, ultrasonography; MRI, magnetic resonance imaging; LR, logistic regression; DT, decision tree; DCIS, ductal Bayes; XGBoost, extreme CBCT, cone-beam computed tomography; RF, random forests; KNN, k-nearest neighbour; BPN, carcinoma in situ; IDC, invasive ductal carcinoma; LMT, logistic model trees; NB, naïve ELM, extreme learning machines;

back propagation neural networks; SVM, support vector machine; AUC, area

## **Author contributions**

Wenjie Shi and Qing-Qing Yu conceived of the presented idea, drafted and reviewed the relevant literature. Leilei Yuan, Weidong Chen and Haibo Zhao contributed to the design of this study. Ya Guo and Heng Zhang contributed to data collection. All authors have read and agreed to the published version of the manuscript.

## **Declaration of conflicting interest**

The authors declare that there are no conflicts of interest.

## **Funding**

This work was supported by the Key R&D Program of Jining (no. 2023YXNS051).

### **ORCID iDs**

Qing-Qing Yu D https://orcid.org/0000-0001-5695-6747

Wenjie Shi https://orcid.org/0000-0002-6478-6802

#### References

- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: **GLOBOCAN** Estimates Incidence and of Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71: 209-249.
- 2. Anaya-Isaza A, Mera-Jimenez L, Cabrera-Chavarro JM, et al. Comparison of Deep Convolutional Networks for the Segmentation of Breast Masses in Mammograms. IEEE Access 2021; 9: 152206-152225.
- 3. Akin O, Brennan SB, Dershaw DD, et al. Advances in oncologic imaging: update on 5 common cancers. CA Cancer J Clin 2012; 62: 364-393.
- 4. Mao N, Yin P, Wang Q, et al. Added Value of Radiomics on Mammography for Breast Cancer Diagnosis: A Feasibility Study. J Am Coll Radiol 2019; 16: 485-491.
- 5. Sakai A, Onishi Y, Matsui M, et al. A method for the automated classification of benign and malignant masses on digital breast tomosynthesis images using machine learning and radiomic features. Radiol Phys Technol 2020; 13: 27-36.

- 6. Zhu YC, AlZoubi A, Jassim S, et al. A generic deep learning framework to classify thyroid and breast lesions in ultrasound images. *Ultrasonics* 2021; 110: 106300.
- Fanizzi A, Losurdo L, Basile TMA, et al. Fully Automated Support System for Diagnosis of Breast Cancer in Contrast-Enhanced Spectral Mammography Images. J Clin Med 2019; 8: 891.
- 8. Wan KW, Wong CH, Ip HF, et al. Evaluation of the performance of traditional machine learning algorithms, convolutional neural network and AutoML Vision in ultrasound breast lesions classification: a comparative study. *Quant Imaging Med Surg* 2021; 11: 1381–1393.
- Liu YY, Tong Y, Wan Y, et al. Identification and diagnosis of mammographic malignant architectural distortion using a deep learning based mask regional convolutional neural network. Front Oncol 2023; 13: 1119743.
- Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. *Nature* 2017; 542: 115–118.
- Franck C, Snoeckx A, Spinhoven M, et al. Pulmonary Nodule Detection in Chest Ct Using a Deep Learning-Based Reconstruction Algorithm. *Radiat Prot Dosimetry* 2021; 195: 158–163.
- Geras KJ, Mann RM and Moy L. Artificial Intelligence for Mammography and Digital Breast Tomosynthesis: Current Concepts and Future Perspectives. *Radiology* 2019; 293: 246–259.
- Cole EB, Zhang Z, Marques HS, et al. Impact of computer-aided detection systems on radiologist accuracy with digital mammography. AJR Am J Roentgenol 2014; 203: 909–916.
- Lehman CD, Wellman RD, Buist DS, et al. Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection. *JAMA Intern Med* 2015; 175: 1828–1837.
- Agarwal R, Diaz O, Llado X, et al. Automatic mass detection in mammograms using deep convolutional neural networks. *J Med Imaging (Bellingham)* 2019; 6: 031409.

- 16. Hamidinekoo A, Denton E, Rampun A, et al. Deep learning in mammography and breast histology, an overview and future trends. *Med Image Anal* 2018; 47: 45–67.
- 17. Kim EK, Kim HE, Han K, et al. Applying Data-driven Imaging Biomarker in Mammography for Breast Cancer Screening: Preliminary Study. Sci Rep 2018; 8: 2762.
- Aboutalib SS, Mohamed AA, Berg WA, et al. Deep Learning to Distinguish Recalled but Benign Mammography Images in Breast Cancer Screening. Clin Cancer Res 2018; 24: 5902–5909.
- Rodriguez-Ruiz A, Lang K, Gubern-Merida A, et al. Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists. *J Natl Cancer Inst* 2019; 111: 916–922.
- Rodriguez-Ruiz A, Krupinski E, Mordang JJ, et al. Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System. *Radiology* 2019; 290: 305–314.
- 21. Chougrad H, Zouaki H and Alheyane O. Deep Convolutional Neural Networks for breast cancer screening. *Comput Methods Programs Biomed* 2018; 157: 19–30.
- Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin 2019; 69: 127–157.
- Saba T, Khan SU, Islam N, et al. Cloud-based decision support system for the detection and classification of malignant cells in breast cancer using breast cytology images. *Microsc Res Tech* 2019; 82: 775–785.
- 24. Al-Fahaidy FAK, Al-Fuhaidi B, Al-Darouby I, et al. A Diagnostic Model of Breast Cancer Based on Digital Mammogram Images Using Machine Learning Techniques. Applied Computational Intelligence and Soft Computing 2022; 2022: 1–17.
- 25. Al-Masni MA, Al-Antari MA, Park JM, et al. Simultaneous detection and classification of breast masses in digital mammograms via a deep learning YOLO-based CAD system. Comput Methods Programs Biomed 2018; 157: 85–94.

 Sannasi Chakravarthy SR and Rajaguru H. Automatic Detection and Classification of Mammograms Using Improved Extreme Learning Machine with Deep Learning. IRBM 2022; 43: 49–61.

- 27. Ragab DA, Sharkas M, Marshall S, et al. Breast cancer detection using deep convolutional neural networks and support vector machines. *PeerJ* 2019; 7: e6201.
- Assiri AS, Nazir S and Velastin SA. Breast Tumor Classification Using an Ensemble Machine Learning Method. *J Imaging* 2020; 6: 39.
- Tan M, Zheng B, Ramalingam P, et al. Prediction of Near-term Breast Cancer Risk Based on Bilateral Mammographic Feature Asymmetry. *Acad Radiol* 2013; 20: 1542–1550.
- Mookiah MRK, Banerjee S, Chakraborty C, et al. Statistical analysis of mammographic features and its classification using support vector machine. Expert Systems with Applications 2010; 37: 470–478.
- 31. de Lima SM, da Silva AG and Dos Santos WP. Detection and classification of masses in mammographic images in a multi-kernel approach. *Comput Methods Programs Biomed* 2016; 134: 11–29.
- 32. Wang J, Yang X, Cai H, et al. Discrimination of Breast Cancer with Microcalcifications on Mammography by Deep Learning. *Sci Rep* 2016; 6: 27327.
- 33. Becker AS, Marcon M, Ghafoor S, et al. Deep Learning in Mammography Diagnostic Accuracy of a Multipurpose Image Analysis Software in the Detection of Breast Cancer. *Invest Radiol* 2017; 52: 434–440.
- Samala RK, Chan HP, Hadjiiski LM, et al. Multi-task transfer learning deep convolutional neural network: application to computer-aided diagnosis of breast cancer on mammograms. *Phys Med Biol* 2017; 62: 8894–8908.
- Bart E and Hegde J. Deep Synthesis of Realistic Medical Images: A Novel Tool in Clinical Research and Training. Front Neuroinform 2018; 12: 82.
- Celaya Padilla JM, Guzman Valdivia CH, Galvan Tejada CE, et al. Contralateral asymmetry for breast cancer detection: A

- CADx approach. *Journal of Applied Biomedicine* 2018; 38: 115–125.
- Patel BK, Ranjbar S, Wu T, et al. Computer-aided diagnosis of contrastenhanced spectral mammography: A feasibility study. *Eur J Radiol* 2018; 98: 207–213.
- 38. Qasem A, Abdullah SNHS, Sahran S, et al. Heterogeneous Ensemble Pruning based on Bee Algorithm for Mammogram Classification. *International Journal of Advanced Computer Science and Applications* 2018: 9: 231–239.
- Perez-Benito FJ, Signol F, Perez-Cortes JC, et al. Global parenchymal texture features based on histograms of oriented gradients improve cancer development risk estimation from healthy breasts. *Comput Methods Programs Biomed* 2019; 177: 123–132.
- Shen L, Margolies LR, Rothstein JH, et al. Deep Learning to Improve Breast Cancer Detection on Screening Mammography. Sci Rep 2019; 9: 12495.
- Agarwal R, Díaz O, Yap MH, et al. Deep learning for mass detection in Full Field Digital Mammograms. *Comput Biol Med* 2020; 121: 103774.
- Arora R, Rai PK and Raman B. Deep feature-based automatic classification of mammograms. *Med Biol Eng Comput* 2020; 58: 1199–1211.
- Samala RK, Chan HP, Hadjiiski LM, et al. Generalization error analysis for deep convolutional neural network with transfer learning in breast cancer diagnosis. *Phys Med Biol* 2020; 65: 105002.
- 44. Schaffter T, Buist DSM, Lee CI, et al. Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Netw Open 2020; 3: e200265.
- 45. Shu X, Zhang L, Wang Z, et al. Deep Neural Networks With Region-Based Pooling Structures for Mammographic Image Classification. *IEEE Trans Med Imaging* 2020; 39: 2246–2255.
- 46. Stelzer PD, Steding O, Raudner MW, et al. Combined texture analysis and machine learning in suspicious calcifications detected by mammography: Potential to

- avoid unnecessary stereotactical biopsies. *Eur J Radiol* 2020; 132: 109309.
- 47. Alhussan AA, Abdel Samee N, Ghoneim VF, et al. Evaluating Deep and Statistical Machine Learning Models in the Classification of Breast Cancer from Digital Mammograms. *International Journal of Advanced Computer Science and Applications* 2021; 12: 304–313.
- 48. Alì M, D'Amico NC, Interlenghi M, et al. A Decision Support System Based on BI-RADS and Radiomic Classifiers to Reduce False Positive Breast Calcifications at Digital Breast Tomosynthesis: A Preliminary Study. *Applied Science* 2021; 11: 2503.
- Chouhan N, Khan A, Shah JZ, et al. Deep convolutional neural network and emotional learning based breast cancer detection using digital mammography. *Comput Biol Med* 2021; 132: 104318.
- 50. Saeed Darweesh M, Adel M, Anwar A, et al. Early breast cancer diagnostics based on hierarchical machine learning classification for mammography images. *Cogent Engineering* 2021; 8: 1.
- 51. Jamal A, Ishak A and Abdel-Khalek S. Tumor edge detection in mammography images using quantum and machine learning approaches. *Neural Computing and Applications* 2021; 33: 1–12.
- 52. Kazemi A, Shiri ME, Sheikhahmadi A, et al. A new parallel deep learning algorithm for breast cancer classification. International Journal of Nonlinear Analysis and Applications 2021; 12: 1269–1282.
- 53. Mahmood T, Li J, Pei Y, et al. An Automatic Detection and Localization of Mammographic Microcalcifications ROI with Multi-Scale Features Using the Radiomics Analysis Approach. *Cancers* (*Basel*) 2021; 13: 5916.
- Samala RK, Chan HP, Hadjiiski L, et al. Risks of feature leakage and sample size dependencies in deep feature extraction for breast mass classification. *Med Phys* 2021; 48: 2827–2837.
- Tran WT, Sadeghi-Naini A, Lu FI, et al. Computational Radiology in Breast Cancer Screening and Diagnosis Using Artificial Intelligence. *Can Assoc Radiol J* 2021; 72: 98–108.

- 56. Zebari DA, Ibrahim DA, Zeebaree DQ, et al. Breast Cancer Detection Using Mammogram Images with Improved Multi-Fractal Dimension Approach and Feature Fusion. Appl Sci 2021; 11: 12122.
- Almalki YE, Khalid M, Alduraibi SK, et al. LBP-Bilateral Based Feature Fusion for Breast Cancer Diagnosis. Computers Materials & Continua 2022; 73: 4103–4121.
- Alruwaili M and Gouda W. Automated Breast Cancer Detection Models Based on Transfer Learning. Sensors (Basel) 2022; 22: 876.
- Altameem A, Mahanty C, Poonia RC, et al. Breast Cancer Detection in Mammography Images Using Deep Convolutional Neural Networks and Fuzzy Ensemble Modeling Techniques. *Diagnostics (Basel)* 2022; 12: 1812.
- 60. Alyami J, Sadad T, Rehman A, et al. Cloud Computing-Based Framework for Breast Tumor Image Classification Using Fusion of AlexNet and GLCM Texture Features with Ensemble Multi-Kernel Support Vector Machine (MK-SVM). Comput Intell Neurosci 2022; 2022: 7403302.
- Annamalai T, Chinnasamy M and Pandian M. A Hybrid Model Particle Swarm Optimization Based Mammogram Classification Using Kernel Support Vector Machine. *Traitement du Signal* 2022; 39: 915–922.
- 62. Chen X, Zhang Y, Zhou J, et al. Diagnosis of architectural distortion on digital breast tomosynthesis using radiomics and deep learning. *Front Oncol* 2022; 12: 991892.
- 63. Dafni Rose J, VijayaKumar K, Singh L, et al. Computer-aided diagnosis for breast cancer detection and classification using optimal region growing segmentation with MobileNet model. *Concurrent Engineering* 2022; 30: 181–189.
- 64. Das HS, Das A, Neog A, et al. Breast cancer detection: Shallow convolutional neural network against deep convolutional neural networks based approach. *Front Genet* 2022; 13: 1097207.
- Houssein EH, Emam MM and Ali AA. An optimized deep learning architecture for breast cancer diagnosis based on improved

marine predators algorithm. *Neural Comput Appl* 2022; 34: 18015–18033.

- 66. Islam W, Jones M, Faiz R, et al. Improving Performance of Breast Lesion Classification Using a ResNet50 Model Optimized with a Novel Attention Mechanism. *Tomography* 2022; 8: 2411–2425.
- Khan AR, Saba T, Sadad T, et al. Identification of Anomalies in Mammograms through Internet of Medical Things (IoMT) Diagnosis System. *Comput Intell Neurosci* 2022; 2022: 1100775.
- Mansour RF and Althobaiti MM. Cognitive Computing-Based Mammographic Image Classification on an Internet of Medical. Computers Materials & Continua 2022; 72: 3945–3959.
- 69. Thirunavukkarasu N. Breast Cancer Semantic Segmentation for Accurate Breast Cancer Detection with an Ensemble Deep Neural Network. Neural Processing Letters 2022; 54: 5185–5198.
- Ramesh S, Sasikala S, Swaminathan G, et al. Segmentation and classification of breast cancer using novel deep learning architecture. Neural Computing and Applications 2022; 34: 1–13.
- Rehman KU, Li J, Pei Y, et al. Architectural Distortion-Based Digital Mammograms Classification Using Depth Wise Convolutional Neural Network. Biology (Basel) 2022; 11: 15.
- Samee NA, Alhussan AA, Ghoneim VF, et al. A Hybrid Deep Transfer Learning of CNN-Based LR-PCA for Breast Lesion Diagnosis via Medical Breast Mammograms. Sensors (Basel) 2022; 22: 4938.
- 73. Wang S, Sun Y, Li R, et al. Diagnostic performance of perilesional radiomics analysis of contrast-enhanced mammography for the differentiation of benign and malignant breast lesions. *Eur Radiol* 2022; 32: 639–649.
- Zahedi F and Moridani MK. Classification of Breast Cancer Tumors Using Mammography Images Processing Based on Machine Learning. *International Journal of Online & Biomedical Engineering* 2022; 18: 31.
- 75. Casal-Guisande M, Alvarez-Pazo A, Cerqueiro-Pequeno J, et al. Proposal and Definition of an Intelligent Clinical

- Decision Support System Applied to the Screening and Early Diagnosis of Breast Cancer. *Cancers (Basel)* 2023; 15: 1711.
- Haraguchi T, Goto Y, Furuya Y, et al. Use
  of machine learning with two-dimensional
  synthetic mammography for axillary lymph
  node metastasis prediction in breast cancer:
  a preliminary study. *Transl Cancer Res*2023; 12: 1232–1240.
- 77. Jones MA, Sadeghipour N, Chen X, et al. A multi-stage fusion framework to classify breast lesions using deep learning and radiomics features computed from fourview mammograms. *Med Phys* 2023; 50: 7670–7683.
- Ali MA, Sahib A and Ali MA. Investigation of Early-Stage Breast Cancer Detection using Quantum Neural Network. *International Journal of Online* and Biomedical Engineering 2023; 19: 61–81.
- Sarvestani ZM, Jamali J, Taghizadeh M, et al. A novel machine learning approach on texture analysis for automatic breast microcalcification diagnosis classification of mammogram images. J Cancer Res Clin Oncol 2023; 149: 6151–6170.
- 80. Barinov L, Jairaj A, Becker M, et al. Impact of Data Presentation on Physician Performance Utilizing Artificial Intelligence-Based Computer-Aided Diagnosis and Decision Support Systems. *J Digit Imaging* 2019; 32: 408–416.
- Bae MS, Han W, Koo HR, et al. Characteristics of breast cancers detected by ultrasound screening in women with negative mammograms. *Cancer Sci* 2011; 102: 1862–1867.
- Romeo V, Pinker K and Helbich TH. Chapter 10 – Breast imaging. *Clinical PET/MRI* 2023; 245–266.
- 83. Singh BK, Verma K, Panigrahi L, et al. Integrating radiologist feedback with computer aided diagnostic systems for breast cancer risk prediction in ultrasonic images: An experimental investigation in machine learning paradigm. Expert Systems with Applications 2017; 90: 209–223.
- 84. Venkatesh SS, Levenback BJ, Sultan LR, et al. Going beyond a First Reader: A

- Machine Learning Methodology for Optimizing Cost and Performance in Breast Ultrasound Diagnosis. *Ultrasound Med Biol* 2015; 41: 3148–3162.
- 85. Song JH, Venkatesh SS, Conant EA, et al. Comparative analysis of logistic regression and artificial neural network for computer-aided diagnosis of breast masses. *Acad Radiol* 2005; 12: 487–495.
- 86. Moustafa AF, Cary TW, Sultan LR, et al. Color Doppler Ultrasound Improves Machine Learning Diagnosis of Breast Cancer. *Diagnostics (Basel)* 2020; 10: 631.
- 87. Zhang Q, Song S, Xiao Y, et al. Dual-mode artificially-intelligent diagnosis of breast tumours in shear-wave elastography and B-mode ultrasound using deep polynomial networks. *Med Eng Phys* 2019; 64: 1–6.
- 88. Liao WX, He P, Hao J, et al. Automatic Identification of Breast Ultrasound Image Based on Supervised Block-Based Region Segmentation Algorithm and Features Combination Migration Deep Learning Model. *IEEE J Biomed Health Inform* 2020; 24: 984–993.
- 89. Lee CY, Chang TF, Chou YH, et al. Fully automated lesion segmentation and visualization in automated whole breast ultrasound (ABUS) images. *Quant Imaging Med Surg* 2020; 10: 568–584.
- Wu T, Sultan LR, Tian JW, et al. Machine learning for diagnostic ultrasound of triplenegative breast cancer. *Breast Cancer Res Treat* 2019; 173: 365–373.
- 91. Qi X, Yi F, Zhang L, et al. Computer-aided diagnosis of breast cancer in ultrasonography images by deep learning. *Neurocomputing* 2022; 472: 152–165.
- 92. Raj JR, Rahman SMK and Anand S. Preliminary evaluation of differentiation of benign and malignant breast tumors using non-invasive diagnostic modalities. *Biomedical Research* 2016; 27: 596–603.
- 93. Hu Y, Guo Y, Wang YY, et al. Automatic tumor segmentation in breast ultrasound images using a dilated fully convolutional network combined with an active contour model. *Med Phys* 2019; 46: 215–228.
- 94. Marcon M, Ciritsis A, Rossi C, et al. Diagnostic performance of machine learning applied to texture analysis-derived

- features for breast lesion characterisation at automated breast ultrasound: a pilot study. *Eur Radiol Exp* 2019; 3: 44.
- 95. Casagrande A, Fabris F and Girometti R. Beyond kappa: an informational index for diagnostic agreement in dichotomous and multivalue ordered-categorical ratings. *Med Biol Eng Comput* 2020; 58: 3089–3099.
- 96. Wang Y, Choi EJ, Choi Y, et al. Breast cancer classification in automated breast ultrasound using multiview convolutional neural network with transfer learning. *Ultrasound Med Biol* 2020; 46: 1119–1132.
- 97. Fei X, Zhou S, Han X, et al. Doubly supervised parameter transfer classifier for diagnosis of breast cancer with imbalanced ultrasound imaging modalities. *Pattern Recognition* 2021; 120: 108139.
- 98. Huo L, Tan Y, Wang S, et al. Machine Learning Models to Improve the Differentiation Between Benign and Malignant Breast Lesions on Ultrasound: A Multicenter External Validation Study. *Cancer Manag Res* 2021; 13: 3367–3379.
- Liu L, Parker KJ and Jung SH. Design and Analysis Methods for Trials with AI-Based Diagnostic Devices for Breast Cancer. J Pers Med 2021: 11: 1150.
- 100. Mishra AK, Roy P, Bandyopadhyay S, et al. Breast ultrasound tumour classification: A Machine Learning-Radiomics based approach. *Expert Systems* 2021; 38: e12713.
- 101. Baek J, O'Connell AM and Parker KJ. Improving breast cancer diagnosis by incorporating raw ultrasound parameters into machine learning. Mach Learn Sci Technol 2022; 3: 045013.
- 102. Hamyoon H, Chan WY, Mohammadi A, et al. Artificial intelligence, BI-RADS evaluation and morphometry: A novel combination to diagnose breast cancer using ultrasonography, results from multi-center cohorts. Eur J Radiol 2022; 157: 110591.
- 103. Hoffmann R, Reich C and Skerl K. Evaluating different combination methods to analyse ultrasound and shear wave elastography images automatically through discriminative convolutional neural network in breast cancer imaging. Int J

Comput Assist Radiol Surg 2022; 17: 2231–2237.

- 104. Homayoun H, Chan WY, Kuzan TY, et al. Applications of machine-learning algorithms for prediction of benign and malignant breast lesions using ultrasound radiomics signatures: A multi-center study. *Biocybernetics and Biomedical Engineering* 2022; 42: 921–933.
- 105. Li C, Huang H, Chen Y, et al. Preoperative Non-Invasive Prediction of Breast Cancer Molecular Subtypes With a Deep Convolutional Neural Network on Ultrasound Images. Front Oncol 2022; 12: 848790.
- 106. Liu W, Guo M, Liu P, et al. MfdcModel: A Novel Classification Model for Classification of Benign and Malignant Breast Tumors in Ultrasound Images. Electronics 2022; 11: 2583.
- 107. Magnuska ZA, Theek B, Darguzyte M, et al. Influence of the Computer-Aided Decision Support System Design on Ultrasound-Based Breast Cancer Classification. *Cancers* (*Basel*) 2022; 14: 277.
- 108. O'Connell AM, Bartolotta TV, Orlando A, et al. Diagnostic Performance of An Artificial Intelligence System in Breast Ultrasound. J Ultrasound Med 2022; 41: 97–105.
- 109. Park KW, Kim SW, Han H, et al. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer. *NPJ Breast Cancer* 2022; 8: 8.
- 110. Pfob A, Sidey-Gibbons C, Barr RG, et al. Intelligent multi-modal shear wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPIRED 002): a retrospective, international, multicentre analysis. *Eur J Cancer* 2022; 177: 1–14.
- 111. Pham TH, Faust O, Koh JEW, et al. Fusion of B-mode and shear wave elastography ultrasound features for automated detection of axillary lymph node metastasis in breast carcinoma. *Expert Systems* 2022; 39: e12947.
- 112. Ragab M, Albukhari A, Alyami J, et al. Ensemble Deep-Learning-Enabled Clinical Decision Support System for Breast Cancer Diagnosis and Classification on

- Ultrasound Images. *Biology (Basel)* 2022; 11: 439.
- 113. Tang Y, Liang M, Tao L, et al. Machine learning-based diagnostic evaluation of shear-wave elastography in Bi-rads category 4 breast cancer screening: a multicenter, retrospective study. *Quant Imaging Med Surg* 2022; 12: 1223–1234.
- 114. Vigil N, Barry M, Amini A, et al. Dual-Intended Deep Learning Model for Breast Cancer Diagnosis in Ultrasound Imaging. Cancers (Basel) 2022; 14: 2663.
- 115. Xu Z, Wang Y, Chen M, et al. Multi-region radiomics for artificially intelligent diagnosis of breast cancer using multimodal ultrasound. *Comput Biol Med* 2022; 149: 105920.
- 116. Zhang GS, Shi Y, Yin PP, et al. A machine learning model based on ultrasound image features to assess the risk of sentinel lymph node metastasis in breast cancer patients: Applications of scikit-learn and SHAP. Front Oncol 2022; 12: 944569.
- 117. Zhu JY, He HL, Lin ZM, et al. Ultrasound-based radiomics analysis for differentiating benign and malignant breast lesions: From static images to CEUS video analysis. Front Oncol 2022; 12: 951973.
- 118. Abbasian Ardakani A, Mohammadi A, Mirza-Aghazadeh-Attari M, et al. An open-access breast lesion ultrasound image database: Applicable in artificial intelligence studies. Comput Biol Med 2023; 152: 106438.
- 119. Lee HJ, Nguyen AT, Ki SY, et al. Classification of MR-Detected Additional Lesions in Patients With Breast Cancer Using a Combination of Radiomics Analysis and Machine Learning. Front Oncol 2021; 11: 744460.
- 120. Hu Q, Whitney HM and Giger ML. A deep learning methodology for improved breast cancer diagnosis using multiparametric MRI. Sci Rep 2020; 10: 10536.
- 121. Hu Q, Whitney HM, Li H, et al. Improved Classification of Benign and Malignant Breast Lesions Using Deep Feature Maximum Intensity Projection MRI in Breast Cancer Diagnosis Using Dynamic

- Contrast-enhanced MRI. *Radiol Artif Intell* 2021; 3: e200159.
- 122. Daimiel Naranjo I, Gibbs P, Reiner JS, et al. Radiomics and Machine Learning with Multiparametric Breast MRI for Improved Diagnostic Accuracy in Breast Cancer Diagnosis. *Diagnostics (Basel)* 2021; 11: 919.
- 123. Lu W, Li Z and Chu J. A novel computeraided diagnosis system for breast MRI based on feature selection and ensemble learning. *Comput Biol Med* 2017; 83: 157–165.
- 124. Saha A, Harowicz MR, Grimm LJ, et al. A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. *Br J Cancer* 2018; 119: 508–516.
- 125. Lo Gullo R, Daimiel I, Rossi Saccarelli C, et al. Improved characterization of subcentimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers. Eur Radiol 2020; 30: 6721–6731.
- 126. Cai H, Liu L, Peng Y, et al. Diagnostic assessment by dynamic contrast-enhanced and diffusion-weighted magnetic resonance in differentiation of breast lesions under different imaging protocols. *BMC Cancer* 2014; 14: 366.
- 127. Cai H, Peng Y, Ou C, et al. Diagnosis of Breast Masses from Dynamic Contrast-Enhanced and Diffusion-Weighted MR: A Machine Learning Approach. *PloS One* 2014; 9: e87387.
- 128. Bickelhaupt S, Paech D, Kickingereder P, et al. Prediction of malignancy by a radiomic signature from contrast agent-free diffusion MRI in suspicious breast lesions found on screening mammography. *J Magn Reson Imaging* 2017; 46: 604–616.
- 129. Antropova N, Abe H and Giger ML. Use of clinical MRI maximum intensity projections for improved breast lesion classification with deep convolutional neural networks. *J Med Imaging (Bellingham)* 2018; 5: 014503.
- 130. Dalmiş MU, Gubern-Mérida A, Vreemann S, et al. Artificial Intelligence-Based Classification of Breast Lesions Imaged With a Multiparametric Breast MRI

- Protocol With Ultrafast DCE-MRI, T2, and DWI. *Invest Radiol* 2019; 54: 325–332.
- 131. Bitencourt AGV, Gibbs P, Rossi Saccarelli C, et al. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. *EBio Medicine* 2020; 61: 103042.
- 132. Chen S, Shu Z, Li Y, et al. Machine Learning-Based Radiomics Nomogram Using Magnetic Resonance Images for Prediction of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Patients. Front Oncol 2020; 10: 1410.
- 133. Demircioglu A, Grueneisen J, Ingenwerth M, et al. A rapid volume of interest-based approach of radiomics analysis of breast MRI for tumor decoding and phenotyping of breast cancer. PLoS One 2020; 15: e0234871.
- 134. Hao W, Gong J, Wang S, et al. Application of MRI Radiomics-Based Machine Learning Model to Improve Contralateral BI-RADS 4 Lesion Assessment. *Front Oncol* 2020; 10: 531476.
- 135. Hu Q, Whitney HM and Giger ML. Radiomics methodology for breast cancer diagnosis using multiparametric magnetic resonance imaging. *J Med Imaging* (Bellingham) 2020; 7: 044502.
- 136. Jiang Z and Yin JD. Performance evaluation of texture analysis based on kinetic parametric maps from breast DCE-MRI in classifying benign from malignant lesions. *J Surg Oncol* 2020; 121: 1181–1190.
- 137. Parekh VS and Jacobs MA. Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging. *Breast Cancer Res Treat* 2020; 180: 407–421.
- 138. Piantadosi G, Sansone M, Fusco R, et al. Multi-planar 3D breast segmentation in MRI via deep convolutional neural networks. Artif Intell Med 2020; 103: 101781.
- 139. Rahbar H, Hippe DS, Alaa A, et al. The Value of Patient and Tumor Factors in Predicting Preoperative Breast MRI Outcomes. *Radiol Imaging Cancer* 2020; 2: e190099.
- 140. Zheng J, Lin DA, Gao Z, et al. Deep Learning Assisted Efficient AdaBoost

Algorithm for Breast Cancer Detection and Early Diagnosis. *IEEE Access* 2020; 8: 96946–96954.

- 141. Avuclu E. A new data augmentation method to use in machine learning algorithms using statistical measurements. *Measurement* 2021; 180: 109577.
- 142. Huang YH, Wei LH, Hu Y, et al. Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer. *Front Oncol* 2021; 11: 706733.
- 143. Lo Gullo R, Wen H, Reiner JS, et al. Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. *Cancers (Basel)* 2021; 13: 6273.
- 144. Montemezzi S, Benetti G, Bisighin MV, et al. 3T DCE-MRI Radiomics Improves Predictive Models of Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. *Front Oncol* 2021; 11: 630780.
- 145. Sayed AM. Machine Learning Augmented Breast Tumors Classification using Magnetic Resonance Imaging Histograms. International Journal of Advanced Computer Science and Applications 2021; 12: 1–9.
- 146. Sun K, Jiao Z, Zhu H, et al. Radiomics-based machine learning analysis and characterization of breast lesions with multiparametric diffusion-weighted MR. *J Transl Med* 2021; 19: 443.
- 147. Zhao YF, Chen Z, Zhang Y, et al. Diagnosis of Breast Cancer Using Radiomics Models Built Based on MRI Dynamic Contrast Enhanced Combined With Mammography. Front Oncol 2021; 11: 774248.
- 148. Baltzer PAT, Krug KB and Dietzel M. Evidence-Based and Structured Diagnosis in Breast MRI using the Kaiser Score. *Rofo* 2022; 194: 1216–1228.
- 149. Castaldo R, Garbino N, Cavaliere C, et al. A Complex Radiomic Signature in Luminal Breast Cancer from a Weighted Statistical Framework: A Pilot Study. *Diagnostics (Basel)* 2022; 12: 499.
- 150. Chen ZW, Zhao YF, Liu HR, et al. Assessment of breast lesions by the Kaiser

- score for differential diagnosis on MRI: the added value of ADC and machine learning modeling. *Eur Radiol* 2022; 32: 6608–6618.
- 151. Fusco R, Di Bernardo E, Piccirillo A, et al. Radiomic and Artificial Intelligence Analysis with Textural Metrics Extracted by Contrast-Enhanced Mammography and Dynamic Contrast Magnetic Resonance Imaging to Detect Breast Malignant Lesions. Curr Oncol 2022; 29: 1947–1966.
- 152. Li H, Whitney HM, Ji Y, et al. Impact of continuous learning on diagnostic breast MRI AI: evaluation on an independent clinical dataset. *J Med Imaging (Bellingham)* 2022; 9: 034502.
- 153. McAnena P, Moloney BM, Browne R, et al. A radiomic model to classify response to neoadjuvant chemotherapy in breast cancer. BMC Med Imaging 2022; 22: 225.
- 154. Ming W, Li F, Zhu Y, et al. Predicting hormone receptors and PAM50 subtypes of breast cancer from multi-scale lesion images of DCE-MRI with transfer learning technique. Comput Biol Med 2022; 150: 106147.
- 155. Daimiel Naranjo I, Gibbs P, Reiner JS, et al. Breast Lesion Classification with Multiparametric Breast MRI Using Radiomics and Machine Learning: A Comparison with Radiologists' Performance. Cancers (Basel) 2022; 14: 1743.
- 156. Rashid HU, Ibrikci T, Paydaş S, et al. Analysis of breast cancer classification robustness with radiomics feature extraction and deep learning techniques. *Expert Systems* 2022; 39: e13018.
- 157. Ren T, Lin S, Huang P, et al. Convolutional Neural Network of Multiparametric MRI Accurately Detects Axillary Lymph Node Metastasis in Breast Cancer Patients With Pre Neoadjuvant Chemotherapy. Clin Breast Cancer 2022; 22: 170–177.
- 158. Romeo V, Clauser P, Rasul S, et al. Alenhanced simultaneous multiparametric F-18-FDG PET/MRI for accurate breast cancer diagnosis. *Eur J Nucl Med Mol Imaging* 2022; 49: 596–608.
- 159. Song SE, Cho KR, Cho Y, et al. Machine learning with multiparametric breast MRI for prediction of Ki-67 and histologic grade

- in early-stage luminal breast cancer. *Eur Radiol* 2022; 32: 853–863.
- 160. Tsuchiya M, Masui T, Terauchi K, et al. MRI-based radiomics analysis for differentiating phyllodes tumors of the breast from fibroadenomas. *Eur Radiol* 2022; 32: 4090–4100.
- 161. Vamvakas A, Tsivaka D, Logothetis A, et al. Breast Cancer Classification on Multiparametric MRI Increased Performance of Boosting Ensemble Methods. Technol Cancer Res Treat 2022; 21: 15330338221087828.
- 162. Wang D, Hu Y, Zhan C, et al. A nomogram based on radiomics signature and deep-learning signature for preoperative prediction of axillary lymph node metastasis in breast cancer. *Front Oncol* 2022; 12: 940655.
- 163. Yoshida K, Kawashima H, Kannon T, et al. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using radiomics of pretreatment dynamic contrast-enhanced MRI. Magn Reson Imaging 2022; 92: 19–25.
- 164. Chiacchiaretta P, Mastrodicasa D, Chiarelli AM, et al. MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER+/HER2- Early Breast Cancer Patients. J Digit Imaging 2023; 36: 1071–1080.
- 165. Stogiannos N, Bougias H, Georgiadou E, et al. Analysis of radiomic features derived from post-contrast T1-weighted images and apparent diffusion coefficient (ADC) maps for breast lesion evaluation: A retrospective study. *Radiography (Lond)* 2023; 29: 355–361.
- 166. Sun K, Zhu H, Chai W, et al. Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer. Front Oncol 2023; 13: 1153261.
- 167. Chebbah NK, Ouslim M and Benabid S. New computer aided diagnostic system using deep neural network and SVM to detect breast cancer in thermography. Quantitative Infrared Thermography Journal 2023: 20: 62–77.
- 168. Arora N, Martins D, Ruggerio D, et al. Effectiveness of a noninvasive digital infrared thermal imaging system in the detection

- of breast cancer. Am J Surg 2008; 196: 523–526.
- 169. Zuluaga-Gomez J, Al Masry Z, Benaggoune K, et al. A CNN-based methodology for breast cancer diagnosis using thermal images. Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization 2021; 9: 131–145.
- 170. Ng EYK, Kee EC and Acharya UR. Advanced technique in breast thermography analysis. 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference, Shanghai, China, 2005, pp. 710–713, doi: 10.1109/IEMBS.2005.1616512.
- 171. Skaane P, Bandos AI, Gullien R, et al. Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. *Eur Radiol* 2013: 23: 2061–2071.
- 172. Houssami N, Bernardi D, Pellegrini M, et al. Breast cancer detection using single-reading of breast tomosynthesis (3D-mammography) compared to double-reading of 2D-mammography: Evidence from a population-based trial. *Cancer Epidemiol* 2017; 47: 94–99.
- 173. Preece AW, Craddock I, Shere M, et al. MARIA M4: clinical evaluation of a prototype ultrawideband radar scanner for breast cancer detection. *J Med Imaging* (Bellingham) 2016; 3: 033502.
- 174. Rana SP, Dey M, Tiberi G, et al. Machine Learning Approaches for Automated Lesion Detection in Microwave Breast Imaging Clinical Data. *Sci Rep* 2019; 9: 10510.
- 175. Uhlig J, Uhlig A, Kunze M, et al. Novel Breast Imaging and Machine Learning: Predicting Breast Lesion Malignancy at Cone-Beam CT Using Machine Learning Techniques. *AJR Am J Roentgenol* 2018; 211: W123–W131.
- 176. Satoh Y, Tamada D, Omiya Y, et al. Diagnostic Performance of the Support Vector Machine Model for Breast Cancer on Ring-Shaped Dedicated Breast Positron Emission Tomography Images. *J Comput* Assist Tomogr 2020; 44: 413–418.

177. Caballo M, Hernandez AM, Lyu SH, et al. Computer-aided diagnosis of masses in breast computed tomography imaging: deep learning model with combined handcrafted and convolutional radiomic features. *J Med Imaging (Bellingham)* 2021; 8: 024501.

- 178. Qi TH, Hian OH, Kumaran AM, et al. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. *Breast Cancer Res Treat* 2022; 193: 121–138.
- 179. Macedo M, Santana M, dos Santos WP, et al. Breast cancer diagnosis using thermal image analysis: A data-driven approach based on swarm intelligence and supervised learning for optimized feature selection. Applied Soft Computing 2021; 109: 107533.
- 180. Oliveira BL, Godinho D, O'Halloran M, et al. Diagnosing Breast Cancer with Microwave Technology: Remaining Challenges and Potential Solutions with Machine Learning. *Diagnostics (Basel)* 2018; 8: 36.
- 181. Zhu D, Wang J, Marjanovic M, et al. Differentiation of breast tissue types for surgical margin assessment using machine learning and polarization-sensitive optical coherence tomography. *Biomed Opt Express* 2021; 12: 3021–3036.
- 182. Zhang J, Chen B, Zhou M, et al. Photoacoustic Image Classification and

- Segmentation of Breast Cancer: A Feasibility Study. *IEEE Access* 2019; 7: 5457–5466.
- 183. Mokni R, Gargouri N, Damak A, et al. An automatic Computer-Aided Diagnosis system based on the Multimodal fusion of Breast Cancer (MF-CAD). *Biomedical Signal Processing and Control* 2021; 69: 102914.
- 184. Moura DC and Guevara López MA. An evaluation of image descriptors combined with clinical data for breast cancer diagnosis. *Int J Comput Assist Radiol Surg* 2013; 8: 561–574.
- 185. Humayun M, Khalil MI, Almuayqil SN, et al. Framework for Detecting Breast Cancer Risk Presence Using Deep Learning. *Electronics* 2023; 12: 403.
- 186. Pfob A, Sidey-Gibbons C, Barr RG, et al. The importance of multi-modal imaging and clinical information for humans and AI-based algorithms to classify breast masses (INSPiRED 003): an international, multicenter analysis. *Eur Radiol* 2022; 32: 4101–4115.
- 187. Nomani A, Ansari Y, Nasirpour MH, et al. PSOWNNs-CNN: A Computational Radiology for Breast Cancer Diagnosis Improvement Based on Image Processing Using Machine Learning Methods. Comput Intell Neurosci 2022; 2022: 5667264.